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 PART I   
GENERAL INTRODUCTION  
1. URBAN LEPTOSPIROSIS 
Leptospirosis is a zoonosis that occurs throughout the world but is most commonly seen in 
tropical climates (1). It has risen as a globally important infectious disease as shown in 
some reports and studies from outbreaks like the 1995 Nicaragua epidemic of severe 
pulmonary haemorrhage syndrome (SPHS)(2,3), identification of disease among US inner-
city homeless population (1,2), the 1998 Lake Springfield Triathlon (2) and 2000 Borneo 
Eco-Challenge (2,4). Moreover, it was traditionally thought that leptospirosis is only a 
major health problem in developing, tropical countries (1,4); however, the disease has been 
under recognized  in urban populations of developed countries as well as in temperate rural 
regions of the world especially during rainy seasons (1,4, 5). But, the real importance of 
the disease is the incidence related to the lack of sanitary infrastructure. Additionally 
poorly understood risk factors, pathogenicity, immunopathology are important factors for 
mortality associated to the disease (1,5,6). Challenges related to prevention are largely 
dependent on sanitation measures which may be difficult to implement, especially in 
developing countries, as our country Ecuador (1,6). 
1.1.  Epidemiology 
Leptospirosis has a changing epidemiology especially in developing countries, as our 
country where it is a significant health burden for poor rural populations (1-4,5). Recently, 
leptospirosis has been recognized as an urban problem. Rural populations have moved to 
cities (5,7) and live in urban slums where the lack of basic sanitation  is evident and 
produces  ecological conditions for rodent-borne transmission (5-7). In South American 
countries such as Ecuador, outbreaks occur yearly in poor urban communities during 
periods of heavy rainfall (8).  Pathogenic spirochetes of the genus Leptospira colonize the 
kidneys of animal carriers such as dogs and rats which eliminate the spirochetes in their 
urine. (6,7) The cycle of infection continues when rainwater washes off leptospires from 
contaminated soil and carries them into puddles,  rivers and flooding water where 
pathogenic Leptospira can survive for long periods of time and can  infect people through 
the contact of this water with their mucosa or lacerated skin (6,8-10).  
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Leptospirosis, traditionally considered an occupational disease (3,7), is now identified 
among people practicing recreational activities (10,11), water sports (1,5), travel and 
adventure tourism (4,5-9,12). However; it continues being under recognized or under 
reported despite the efforts of Leptonet, a surveillance system developed by the 
International Leptospirosis Society. (13) 
Syndrome-based or febrile cases analysis have been effectively used in outbreaks (6,14,15) 
and found that a large proportion of leptospirosis cases had been unrecognized or attributed 
to other tropical diseases, because clinical symptoms are very similar to other illnesses 
(2,11,16). Also, in our countries, surveillance underestimates the impact of leptospirosis, 
because clinical diagnosis is difficult, in fact, classical severe manifestations do not differ 
from other febrile syndromes; for example, in some studies leptospirosis was found to be 
the cause of disease in many of the patients with non-viral hepatitis jaundice and non-
malarial fever (9,16). Also, only a few laboratories carry out paired serum analysis and 
perform the standard diagnostic test, microagglutination test (MAT) (8,16). 
There is a wide range of clinical manifestations, some people can develop mild 
symptomatic infections while others develop severe hemorrhagic disease forms such as 
Weil’s disease (jaundice, acute renal failure and bleeding) (6,9) and SPHS (severe 
pulmonary hemorrhagic syndrome) (3). In some studies it was found that asymptomatic 
infections occurred in 60–70% of all serologically identified infections (11).  
Adult males suppose to have increased risk for acquiring  leptospirosis due to their habitual 
jobs that are related with risk factors; however, recently it was noticed that young urban 
slum residents had serologic evidence of infection, especially after exposure to floods 
(14,17). The disease is commonly seen during rainy seasons in some populations 
inhabiting slums such as Guayaquil lacking sanitary infrastructure. In such a conditions 
women and men had similar risk for acquiring infection (14,18). Epidemiological studies 
are useful for identifying  risk factors and guided efforts (interventions) to control the 
disease. (10,11,19).  
In urban slums in developing cities and countries, there are infrastructural deficiencies, 
such as open sewers, exposed garbage and numerous rodents that contribute to the 
transmission of leptospirosis during epidemics, especially during rainy seasons (7,8,13,16). 
Chemoprophylaxis as a prevention method may be useful in very small groups; however, it 
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won´t be of much use in large risk populations. Vaccination of domestic animals is also 
very important but wild reservoirs are difficult to handle for  vaccination purposes (12). 
1.2. Clinical and laboratory diagnosis 
Antibiotic therapy provides the greatest benefit when initiated early, this emphasized the 
importance of early diagnosis (12). However, it is difficult to assess because severe late-
phase disease shows the classic manifestations of the infection but early-phase 
leptospirosis has non-specific presentation which can be misdiagnosed and confounded 
with other febrile illness (20,21). Moreover, misdiagnosis has become critical, where 
dengue and other infectious diseases with similar clinical presentations are endemic 
(17,22). Co-infection with diseases such as scrub typhus and malaria have been reported 
and presents another challenge in the diagnosis due to their unspecific syndromes similar 
to the ones produced by leptospirosis.  (23). Most cases of leptospirosis probably remain 
unrecognized unless the diagnosis is suggested by a specific exposure or  when the disease 
occurs in the context of an outbreak (7-10,15,23) 
There is also lack of adequate laboratory tests for confirmatory diagnosis (8). MAT is the 
best tool so far,  however it is necessary to have paired serum samples, as well, it is 
necessary to culture leptospiral strains which is difficult and risky (24). Efforts have 
focused on developing serologic tests that use whole Leptospira antigen preparations to get 
an easier diagnostic test. (25-28). 
ELISA tests has shown to be a useful tool for the diagnosis of leptospirosis; however, some 
reports show low sensitivities during acute-phase illness, in fact it may detect fewer than 
25% cases during the first week of illness (30-32). Screening for immunoglobulin M 
antibodies was evaluated for its ability to detect human leptospirosis (31,32), but these 
tests exhibited less sensitivity compared with Leptospira MAT (24,31). Sensitivity appears 
increased during the second week of illness, and testing of a late acute-phase sample (after 
ten days of illness) is therefore recommended; however, antibodies may persist for years 
after exposure. PCR based diagnosis of leptospirosis cannot identify the infecting serovar, 




The currently gold standard is microscopic agglutination test (MAT) due to its high 
sensitivity and specificity but it does not permit early diagnosis because it cannot detect 
infection until 5–7 days after exposure. (24,25,31,36). Development of several other 
diagnostic methods, including serologic testing as immunofluorescence, enzyme-linked 
immunosorbent assay, and Western blot analysis has been reported. (37-43) 
Several assays based on targeting genes such as those encoding OmpL1, DNA gyrase, 
RpoB, Lig, LipL32/Hap1, putative transcriptional regulator, and repetitive DNA elements 
have therefore been developed (40). Real-time, quantitative TaqMan PCR has also been 
developed. Several assays have been developed to overcome the typing of Leptospira spp., 
such as single-strand conformation analysis, restriction enzyme analysis of PCR products, 
direct sequencing of amplicons, low-stringency single specific PCR, and multilocus 
variable number tandem-repeat analysis (43-48). A multiplex PCR assay to differentiate 
pathogenic and saprophytic Leptospira has also been developed. (47) 
Epidemiologic tools such  as serologic and molecular typing can be useful because 
knowing the prevalent serogroup could be the first step to identify reservoirs and generate 
control strategies; however, reliable molecular strategies are not available yet, so results 
from MAT testing of patient sera would be used as a surrogate to infer the infecting 
serogroup. Pulsed-field gel electrophoresis, 16S rRNA sequencing or PCR-based typing 
methods have not gained wide acceptance because of their limited discriminatory power, 
lack of adequate electronic databases of typing and sequence patterns or low 
reproducibility. (27,29,34,49) 
1.3. Pathophysiology and clinical management 
As shown in figure 1, clinical manifestations range from an influenza-like illness to 
fulminant disease with jaundice, acute renal failure, aseptic meningitis, and hemorrhagic 
diathesis like Weil’s disease and SPHS (50) Early diagnosis is important since 
complications depend on the age population, because older adults have an increased risk 
for death, require aggressive treatment and monitoring (50). Prognostic factors for 
mortality are hypokalemic acute renal failure, respiratory insufficiency, hypotension, 
arrhythmias and altered mental status. (51,52). 
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Figure 1. Clinical Syndromes caused by Leptospira  Adapted  From: Zunino M, Pizarro P. Leptospirosis: Puesta al día. Rev. chil. infectol.2007, vol.24, n.3, 
Leptospirosis-associated SPHS is now recognized as a widespread public health problem.  
It should be suspected when the patients show signs of respiratory distress, without 
haemoptysis (3,51). SPHS patients seem to have a high (approximately 1000000 
bacteria/mg) leptospiral load in the lungs (52). However, few intact leptospires are 
observed in autopsy, suggesting an immune-mediated process with immunoglobulin and 
C3 deposited along the alveolar basement membrane. (51-54).  
Acute and fulminant pulmonary edema (PO) or acute lung injury (ALI) has been reported 
(52). Lung parenchyma showed a marked increase in inducible nitric oxide synthase 
(iNOS) activity, suggesting that iNOS and nitric oxide (NO) may also play a role in the 
pathogenesis of PO, but the mechanisms remain unclear (53). 
The renal failure causes impaired proximal sodium reabsorption, increased distal sodium 
delivery and potassium wasting (55,56). The target may be the sodium–potassium–chloride 
co-transporter since leptospiral outer membrane extracts inhibit transporter activity and 
leptospiral derived unsaturated fatty acids act as toxins that inhibit kidney sodium–
potassium ATPase (57,58). 
Weil made the first description of the disease in 1886; therefore, it is called Weil’s disease, 
the most severe form of leptospirosis (59). This presentation, with high fever, intense 
jaundice related with elevations of liver transaminases, hemorrhagic diathesis requiring 
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vitamin K, hepatic and renal dysfunction, mental status changes, cardiovascular collapse, 
and significant mortality, is not always present (52,59).  
1.4. Genome and microbiology 
The genomes of serovar L. interrogans serovars Icterohaemorrhagiae and Copenhageni 
were published in 2003 and 2004, respectively (9,61). A database, is available online for 
comparison of the two genomes (13,60). Leptospiral genome is formed by two circular 
chromosomes (figure 2), the chromosome I with approximately 4.3 Mb and the 
chromosome II with approximately 350 kb which is highly conserved among the serovars 
that are members of the same serogroup. (9)  
Figure2.  L. interrogans Lai 
genome. a. Large chromosome 
(CI); circles range from 1 (outer) 
to 6 (inner) kilobases; b. small 
chromosome (CII); circles from I 
(outer) to IV (inner) kilobases. 
Genes on forward and reverse 
strand; tRNA genes; rRNA genes; 
GC bias ((G-C)/(G + C); G + C 
content (from circle 1 to 6 
respectively). They are 
represented as follows: amino 
acid biosynthesis(orange), 
purines, pyrimidines, nucleosides 
and nucleotides(green), fatty acid 
and phospholipid 
metabolism(blue), biosynthesis of 
cofactors, prosthetic groups and 
carriers(magenta), central 
intermediary metabolism(khaki), energy metabolism(cyan), transport and binding proteins(orchid), DNA metabolism(yellow), transcription(dark green), 
protein synthesis (brown), protein fate (red), regulatory functions(green-yellow), cell envelope(pink), cellular processes(salmon), other categories(navy), 
conserved(light grey), hypothetical(dim grey), unknown function protein(slate grey), tRNA and rRNA(black)  FROM Ren SX, Fu G, Jiang XG, et al. 
Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature 2003; 
422:888–893.  
These genomes contained 4,768 and 3,728 predicted open reading frames (ORFs), and 118 
and 64 unique ORFs respectively (6,9,61). Lipopolysaccharide (LPS) is believed to 
influence reservoir specificity Icterohaemorrhagiae and Copenhageni are the striped field 
mouse (Apodemus agrarius) and the domestic rat (Rattus norvegicus), respectively (9).  
Unlike other spirochaetes, Leptospira have a haem biosynthesis and uptake pathway , and 
an alternative pyruvate pathway which is used to synthesize isoleucine (62,63).  Leptospira 
also has three toxin – antitoxin systems that may mediate global gene regulation during 
nutritional stress. Moreover, Leptospira have over 70 genes with putative regulatory roles; 
this repertoire is more than twice the number seen in other spirochetes (61,64). It has also 
genes encoding flagellin and recA (65). Importance of host-induced genes infection 
processes have been determined to be coordinately regulated or stimulated by host factors. 
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The genomic sequences of L. interrogans serovar Icterohaemorrhagiae (Lai strain) and L. 
interrogans serovar Copenhageni strain Fiocruz L1–130 indicate that there is no plasmid in 
Leptospira spp. (9,61). 
1.5. Pathogenesis 
Disease determinants are inoculum size, host factors and the pathogen’s virulence 
characteristics. The inoculum size could be influenced by repeated exposure (risk 
associations) like the relation of urban slum resident and open sewer or flooding water (8, 
18).  
Identification of host genetic susceptibility factors for leptospirosis in outbreak 
investigations can provide clues in disease pathogenesis, as host factors involvement (67). 
It was found an association between HLA-DQ6 genotype and the risk of acquiring 
leptospirosis by swallowing water; however It could be related with the inoculum´s size 
effect (61) . 
The pathology of leptospirosis seems to have an underlying immunopathogenic process. 
Poor outcomes in patients have been proved to be related with differences in plasma tumor 
necrosis factor (TNF)-α levels. Whole Leptospira induces type 1 cytokines from whole 
blood of naıve individuals (68). Leptospira led to expansion of γ−δ cells at high 
concentration of bacteria and α−β T at low numbers of Leptospira. Stimulated γ−δ T cells 
release IFN-γ without antigen processing. Leptospira LPS activates cells through Toll-like 
receptor-2 which is associated to a unique structure of Leptospira lipid A. Also, leptospiral 
glycolipoprotein induce naıve PBMCs to secrete TNF-α and IL-10 and induce cell 
activation (69-72). 
1.6. Virulence  
The ability of the pathogen to rapidly penetrate and disseminate through intercellular 
junctions, and establish persistent colonization in the renal tubules is a characteristic of 
leptospirosis (73,74). It has been proposed that O - antigen regulation may determine 
whether Leptospira cause acute disease or persistent infection. (2,73). Nally and colleagues 
noted that features of the lipopolysaccharide O antigen (Oag) content of leptospires in 
guinea pig liver was markedly reduced compared to that of organisms found in rat renal 
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tubules or cultivated in vitro. Their findings show an association of Oag loss with 
disseminated lethal infection and an association of Oag with renal tubular colonization 
(73), but these results aren´t well accepted and need to be reproduced in Vivo. 
Nevertheless, the lipopolysaccharide O antigen is well known as virulence factor, and it is 
probably that its modifications let the bacteria to escape from antibody elimination (13) 
Based on genomic data, there are over 260 membrane-associated surface proteins (75). 
Studies have tried to evaluate differential expression of target genes when cultured under 
conditions that mimic the host environment (61,76) and to confirmed surface expression 
with immunofluorescence and electron microscopy, immunochemical analysis of outer 
membrane vesicles and ELISA with intact Leptospira (59,76,77). 
There are reported six surface proteins, these include porin OmpL1; peripheral protein 
P31LipL45; lipoproteins LipL41, LipL32, LipL21 and LipL48 and over 10 candidate 
proteins related con leptospiral pathogenesis (75-77). LipL32 and LipL21 are very 
interesting because they are related to all pathogenic Leptospira (75,76). A very important 
finding has been the identification of a set of proteins that are called Lig proteins that are 
90-amino acid bacterial immunoglobulin-like proteins (Big) which are related to virulence 
factors such as intimin, invasin and BipA proteins (41,75). Another interesting discovery is 
that lig genes, that include ligA and ligB and a pseudogene ligC, are present only in 
pathogenic Leptospira species.  These genes encode two large lipoproteins surface 
expressed that are reduced when virulent strains are attenuated during culture passage (76). 
Furthermore, these proteins have been shown to confer protective immunity and they could 
serve as serodiagnostic markers for infection (79) 
1.7. Vaccines and immunity 
Vaccines are supposed to be used as prevention against the disease in humans or limiting 
the spread of transmission to humans in reservoirs. Bacterin vaccines have been used for 
years in the veterinary field all over the world; however, Cuba and China use them in 
humans. (80-82). 
 Some authors identified surface-exposed proteins conserved across pathogenic serovars 
and may elicit cross-protective immunity (83,84). LipL41 and OmpL1 recombinant 
immunization induced protective responses in hamsters (77,84). It was found also that 
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immunization with a viral construct which encodes Hap1 (LipL32) can confer protection 
(75, 83). Lig proteins are also candidates to develop effective vaccines  (76,78).   
Immunity has been believed to be antibody-mediated because it was found that 
immunization can be passively transferred in hamsters (85). However, most of responses 
were found to be correlated with Th1 responses, characterized by CD4 and γ−δ T cell 
production of IFN-γ. So the efforts will be focus on developing strategies to enhance these 
types of immune responses. (80,86,87) 
1.8. Treatment 
Despite the fact that we are currently 60 years into the antibiotic era, the optimal treatment 
approach for leptospirosis is not clearly defined (88). As is resumed in table 1, recent 
human studies suggest that the later generation cephalosporins, namely ceftriaxone and 
cefotaxime, are likely the treatment of choice in cases of suspected or confirmed 
leptospirosis (80). The once-daily dosing and broad spectrum of activity of ceftriaxone 
make it a particularly attractive option. If these medications are not available, the classic 
treatments of penicillin and doxycycline remain viable options. The macrolides appear 
effective in the therapy of at least mild disease. The aminoglycosides are often used as 
first-line therapy, but we are hesitant to recommend their use due to nephrotoxicity. The 
fluoroquinolones hold promise as potential therapies, but there are not currently enough 
human data to support their use. Further research into this important but often overlooked 
disease is clearly needed. (90,91) 
TABLE 1 Treatment options for leptospirosis. Taken from Griffith M, Hospenthal D, Murray C. 
Antimicrobial therapy of leptospirosis. Curr Opin Infect Dis 2006 19:533–537 
 







Cefepime or extended 
spectrum penicillins or 
carbapenems 
Mild to moderate 
Disease Doxycycline 
Azithromycin or amoxicillin 




2. Dengue  
Dengue is known as the most important human arboviral disease worldwide (92,93). In 
some regions it is endemic and has a potential of generating epidemics usually associated 
with the rainy season, despite the control strategies of health authorities which are for the 
most cases insufficient to avoid transmission (94). Incidence of dengue hemorrhagic fever 
is increasing due to the circulation of more than one viral serotype, DEN-1, DEN-2, DEN-
3, DEN-4 (94-96).  This and other epidemiological factors add up so that dengue is 
currently considered one of the most serious public health concerns (94,97). Identification 
of recurrences and isolation of severe cases reflect the lack of efficient control strategies 
and adequate epidemiological surveillance systems (146).  Among the many aspects on 
dengue epidemiology to better develop a control to annual outbreaks, one of the main 
problems is the difficulty in the correct identification of dengue cases (92-94,98). 
2.1. Epidemiology 
Dengue is now endemic in more than 100 countries in Africa, America, Eastern Mediterranean, 
Western Pacific, and particularly in South East Asia and it is of deep concern that its global 
prevalence has grown dramatically in recent years (99). 
Dengue virus  belong to the Flavivirus genus within the Flaviviridae family (single 
stranded positive sense RNA viruses) and it is found in tropical and subtropical areas 
where environmental conditions favor the presence and breeding of its vector, the Aedes 
aegypti mosquitoes. (94,100). In the Americas, dengue was first recognized in the 18th 
century, and largely eradicated during the 1950-60’s due to intense vector control 
strategies. Re-introduction occurred after intensive top-down approaches to eradicate 
vectors ceased in the 1970’s and soon dengue spread in the Caribbean and Central America 
and re-emerged in Ecuador in 1988 (101). The World Health Organization (WHO) 
indicates that South-East Asian and Western Pacific Regions bear nearly 75% of the 
current global disease burden (94,100). 
Dengue haemorrhagic fever (DHF) was first recognized in Manila in 1954 especially 
infecting children and was characterized by the acute onset of high fever, petechial 
haemorrhage and shock.(102,103) In 1958, an outbreak of DHF occurred in Bangkok 
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becoming a serious public health problem, causing morbidity and mortality among children 
in many regions of world (104,105)  
Mosquitoes of the genus Aedes, subgenus Stegomyia, like Aedes aegypti and A. albopictus 
are the main epidemic vectors which are well established in tropical and subtropical 
regions as peridomiciliary mosquitoes (100,106). Aedes aegypti, the main vector, is well 
adapted to urban life and typically breeds in clean, stagnant water like rain water, thus the 
illness usually increases during rainy seasons where mosquitoes are more abundant (93-
96,106).  
WHO has classified dengue as a significant health, economic, and social problem on 
endemic and hyperendemic areas where usually the four serotypes circulate (94,95). The 
incidence and prevalence vary from year to year, with epidemics every 3 to 5 years. 
Multiple factors are responsible for the dynamic patterns of transmission of the disease: 
population growth, rapid uncontrolled urbanization, increased movement of viruses via 
international travel, demographic changes, poor vector control, genetic changes in the 
virus, immunological profile and modulating climatic factors. (98,107-109)  
El Niño Southern Oscillation (ENSO) and global warming are also known as other factors 
contributing to the cyclical pattern of dengue activity (97,98). Furthermore, if it is seasonal 
within a year in most endemic countries it is related to seasonal rainfall and temperature 
changes(107,109), its greatest burden in endemic countries is concentrated in children 
(110,111). The spread of infection is also enhanced by traveling which facilitates the 
transmission of infected individuals and mosquito larvae to non-infected areas (112,113). 
2.2. Clinical and laboratory diagnosis 
Dengue virus infection is clinically similar to many other acute tropical diseases where 
fever is the main symptom, thus  laboratory testing and confirmation of clinical diagnosis 
is very important in early diagnosis and patient management (20,59,114). 
Dengue symptoms range from a self-limiting infection to the life-threatening dengue 
complications such as hemorrhagic fever and dengue shock syndrome (DHF/DSS)(113). 
Classical dengue causes headache, retro-orbital pain, myalgia, arthralgia, rash, 
haemorrhagic manifestations, leucopenia; whereas dengue haemorrhagic fever include in 
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addition to fever (or history of acute fever) lasting two to seven days, haemorrhagic 
tendencies (positive tourniquet test; petechiae; ecchymoses or purpura; bleeding from the 
mucosa, gastrointestinal tract, injection sites, or other locations; haematemesis or melena; 
and thrombocytopenia (≤100 000×106 cells/l).  (115). Nevertheless, final diagnosis should 
be based only on laboratory confirmation of dengue especially in areas where other 
diseases causing similar symptoms are also present (115,116)  
The laboratory diagnostics of dengue include methods for detection of the virus (by cell 
culture, immunofluorescence), detection of virus antigen (ELISA), detection of anti-
dengue virus antibody by hemagglutination inhibition-HI or complement fixation test (CF), 
neutralization tests and detection of virus nucleic acid (RT-PCR) (116, 117) . 
However, for a confirmatory molecular diagnosis viruses should be identified by isolation 
or nucleic acid detection. Commercially kits have been developed for the rapid detection of 
dengue infections (118,119). These kits are designed to detect the presence of NS1 antigen 
and/or anti-dengue antibodies (99,119). The detection for clinical application has been 
described in ELISA and RDTs. (118,121,122).   
Rapid diagnostic tests (RDTs) for IgM and IgG antibodies detection have shown to be 
efficient and use low-technology (120). The tests are based on detecting IgM antibodies 
and/or NS1 antigens. NS1 is detectable in the first 5 to 6 days of infection in contrast to 
IgMs that only develop after 4 to 5 days of infection with the virus. IgM antibodies 
detection by RDTs generally has a higher sensitivity (118,123,124), however, RDTs that 
detect NS1 antigens are highly sensitive and specific for the early stages of the infection. 
(125).  
The use of anti-dengue IgM and IgG antibody detections allow the classification of 
primary and secondary (or later) dengue infections respectively (120,126). This improves 
patient management because dengue patients are commonly identified during secondary 
infections which is associated to severe clinical complications.(117)  
Instrumental methods such as quartz crystal microbalance, surface plasmon resonance, 
photonic crystal and electrochemical impedance spectroscopy have shown promising 
results. Nanosized materials including liposomes, nanowires and nanopores, coupled to 
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conventional fluorescence, potentiometry and voltammetry methods are also described and 
could be valuable diagnostic tools. (127) 
2.2.1. 
These methods include hemagglutination-inhibition (HI), complement fixation (CF), 
neutralization test (NT), immunoglobulin M (IgM) capture enzyme linked immunosorbent 
assay (MAC-ELISA) and indirect immunoglobulin G ELISA. Despite these are useful, 
they show high cross-reactivity, among serotypes and with other flaviviruses (yellow fever 
virus, Japanese encephalitis virus, or St. Louis encephalitis virus), and others like 
Oropouche, Mayaro or Chikungunya viruses. (128) 
Hemagglutination-inhibition test (HI) was the standard method used before due to its high 
sensitivity and relatively easy execution. However, it lacks specificity, require  paired 
samples, and can´t identify serotypes. Complement fixation test (CF) is not used for 
routine dengue diagnosis; it is based on the fact that the complement will be consumed 
during the antigen-antibody reaction. (129) 
Neutralization test (NT) is the most sensitive and specific serological test for diagnosis and 
serotyping. The disadvantages are its high cost, the long time necessary to perform the 
assay and the associated technical difficulties (128). Finally, ELISA is considered the most 
useful test for diagnosis to detect acute phase (IgM) and convalescent phase (IgG) 
antibodies. (128-132)  
Immunoglobulin M (IgM) capture enzyme linked immunosorbent assay (MAC-ELISA) is 
less sensitive but its specificity is similar to that of HI in primary and secondary infections 
(129,133). Other ELISA´s techniques for the detection of total immunoglobulin of 
flavivirus have been described and used only in seroepidemiological studies(131,132-136). 
Hemolysis in gel, the hemoadsorption immunosorbent technique and the staphylococcal 
agglutination-inhibition reaction were techniques that have also used in the past.(137-139)  
Serologic Diagnosis  
2.2.2. 
Four methods are routinely used; intracerebral inoculation of newborn mice, inoculation on 
mammalian cell cultures, intrathoracic inoculation of adult mosquitoes, and inoculation on 
Viral Isolation  
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mosquito cell cultures. (116, 128). Intracerebral inoculation can detect the four serotypes in 
mice; however, it has high cost, long time for isolation, and low sensitivity (140,141). 
Mammalian cell culture presents the same disadvantages, although this method seems to be 
very commonly used. (128)  
Mosquito inoculation is the most sensitive but least used method. Aedes aegypti, A. 
albopictus, Toxorhynchities amboinensis and T. splendens are used to perform the test. The 
viral detection is made through indirect immunofluorescence assay (IFA) on mosquito´s 
brain or salivary glands (135). Mosquito cell culture is the most recent methodology 
developed, it is a quick, sensitive and relatively inexpensive. The mosquito cells are 
relatively easy to maintain and grow at room temperature and it is possible to keep cultures 
for up to 14 days without replacing  the medium (116,142,143).  
2.2.3. 
Nucleic acid hybridization using RNA either with biotinylated probes or 32P-labelled 
probes is used primarily in epidemiological studies as a research tool rather than a routine 
diagnostic method (144,145). Reverse transcription - Polymerase Chain Reaction (RT-
PCR) has been developed but it depends of many variables. Furthermore, according to the 
World Health Organization (WHO), despite PCR is a powerful method to be used for 
dengue diagnosis, it still needs to be better standardized. (146-149)  
New immunohistochemical methods consisting of monoclonal or polyclonal antibodies 
labeled with peroxidase/ alkaline-phosphatase enzymes that detect virus on a great variety 
of fixed samples have been also used and evaluated(150). In addition to specific 
amplification and restriction enzyme analyses, other studies have demonstrated that 
nucleotide sequencing of gene fragments amplified by RT-PCR can be used as a fast 
method for classification of dengue virus serotypes and phylogenetic studies (146,151).  
Molecular Detection  
2.3. Pathophysiology and clinical management 
Early diagnostic of dengue infection allows for timely clinical intervention and etiological 
investigation (99). Diagnosis of disease during the acute phase should be a priority for 
public health programs because dengue virus could cause significant pathologies including 
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death of the patient (152,153). In the last century dengue fever became one of the leading 
causes of morbidity and mortality throughout the tropics (94,113).  
The main explanation for the progression of dengue symptoms and complications has been 
associated to  "antibody-dependent enhancement" (ADE) which means that enhancing 
antibodies acquired at primary infection increase the number of infected cells, and thus the 
levels of viremia, during secondary infection (114,154) . 
The World Health Organization (WHO) classified Dengue due to clinical manifestations in 
Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF), and Dengue Shock Syndrome 
(DSS) (155).  The definition for DF must meet four criteria: fever, minor hemorrhagic 
manifestations, and thrombocytopenia. In turn, DHF is divided into four grades (DHF I–
IV), where Grades III and IV are DSS, with hypotensive shock or narrow pulse pressure 
plus clinical signs of shock. However, limitations have been noted regarding its complexity 
and applicability, particularly in patients with severe symptoms.(156-159). A new 
classification has been propose, assigning clinical symptoms into Dengue without Warning 
Signs, Dengue with Warning Signs, and Severe Dengue (see treatment) (113,155,159). 
The immunopathogenesis remains poorly understood but the target cells for dengue virus 
include dendritic reticulum cells, monocytes, lymphocytes, hepatocytes, and vascular 
endothelial cells (154). The virus binds to Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN) which has a high affinity for ICAM3, 
expressed in activating T-cells (154,160,161). In mature dendritic cells, antibodies can 
enhance dengue infection via Fc receptors and then T-cells become activated and generate 
abundant cytokines, including tumor necrosis factor-alpha, interleukins (IL-2, IL-6, and IL-
8), implicated in vascular leak and shock in addition to activating effector cells (154,162) . 
The virus manipulates many different cellular pathways, including autophagy. For 
example, DENV2 infection of a hepatocyte cell line induce autophagy due to virus induced 
autophagosomes co-localized with a marker of lysosomal fusion (LAMP1) (163). Also, 
NS1 is co-localized with autophagosomes as well as LAMP1 and the ribosomal protein 
L28 (163-165). An endosomal marker (M6P-R) co-localized with autophagosomes 
indicates that some autophagosomes may fuse with endosomes to form organelles called 
amphisomes. (163,166) Virus replicates on virally induced characteristic double membrane 
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vesicles (DMVs), and autophagosomes are DMVs, it has been hypothesized that it might 
replicate on amphisomes and thus link virus entry and replication. (163-166) 
T-Cell Activation and Apoptosis may lead to the sudden onset of vascular permeability and 
hemorrhage that characterizes severe forms of dengue disease (168). T-cell response may 
cause suboptimal killing of the infected monocytes and serve to augment the severity of the 
second infection due to higher viral loads (168,169). Dengue virus can also attach to the Fc 
receptors on macrophages, monocytes, and other cells when the virus is coated with 
antibody. The antibody actually enhances the infectivity of these viruses by providing new 
receptors for the virus and promoting viral uptake into target cells and it is mostly related 
with the severity of secondary infection with a different virus serotype (169-171). Most of 
the flaviviruses are serologically related, and antibodies may neutralize or enhance another 
virus. (128) 
Most infections produce, in decreasing order of frequency, an asymptomatic infection, 
mild nonspecific symptoms, or classic dengue (94, 169). The more severe manifestations 
of shock and hemorrhage occur only in 5% of infections (169). The greatest risk factor for 
the development of severe dengue is secondary infection with a different dengue serotype 
from the original infecting virus (168,172). Severe illness during secondary dengue 
infections was associated with higher peak plasma virus titers (172). 
2.4. Genome and microbiology 
Studies of dengue virus evolution are possible thanks to increasing availability of viral gene 
sequence data (173-175). DENV sequences have shown remarkable stability over the 
entire history as evidenced in the NCBI Entrez protein database. Hence, these conserved 
sequences are unlikely to significantly diverge in newly emerging DENV isolates in the 
future (174). There is high rate of clade extinction with fluctuations in genetic diversity. It 
is possible that genetic variations are synonymous and moreover deleterious acting as a 
constraint to Dengue evolution, apparently, recombination is the most debated mechanism 
of viral variation; however, the variations tend to be deleterious which reduce fitness and 
therefore is cleared by purifying selection (173,174).Dengue virus has a relatively recent 
evolutionary history, with the four serotypes establishing endemic transmission in humans 
in the last few hundred years. There is evidence that viral strains differ in key phenotypic 
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features such as virulence, and for positive selection at immunologically important sites. 
(175) 
Dengue as other flaviruses has a positive-stranded RNA genome, an icosahedral capsid, an 
envelope and varies from 40 to 65 nm in diameter (173). The E viral glycoprotein folds 
over, pairs up with another E glycoprotein, and lies flat across the surface of the virion to 





Figure 3. Structure of Flavivirus Dengue. Taken from Murray et al: Medical 
Microbiology; 6th edition.  
 
 
The virus initiates infection of a permissive cell via clathrin-mediated endocytosis and then 
releases its genomic RNA into the cytosol after fusing with the late endosome 
(166,163,176). The entire viral RNA is translated as one open reading frame into a single 
polyprotein, and is subsequently cleaved by cellular and viral proteases to release three 
structural proteins and seven non-structural proteins (163).  
The non-structural proteins, including four nonstructural early proteins called NS 1 through 
4, a protease and an RNA-dependent RNA polymerase act to replicate the viral genome 
and assemble the new virions (177,178). In fact, a full-length, 42S, negative-sense RNA is 
synthesized as a template to produce more 42S positive-sense mRNA (176,178). The NS1 
is a highly conserved glycoprotein that is present in all serotypes and during the early 
clinical phase of disease (128). 
 In addition, a 26S late mRNA is transcribed from the template which encodes the capsid 
(C) and envelope (E1 through E3) proteins (99,123,176,178). The structural genes are at 
the 5'-end of the genome so they are synthesized first and with the greatest efficiency. This 




Figure 4. Dengue Genome 
map. Taken from Murray et al: 
Medical Microbiology; 6th 
edition.  
 
2.5. Pathogenesis  
Dengue hemorrhagic fever is primarily a disease of infants and children (94, 168), 
although adults may also be afflicted with severe disease (171). Unlike other infectious 
diseases, severe forms of dengue are more common in well-nourished children, and 
malnutrition protects against severe dengue vasculopathy. This negative association may 
be related to suppression of cellular immunity in malnutrition (168,179). 
The viruses attach to specific receptors expressed on many different cell types from many 
different species. Then they enter the cell by endocytosis fusing its membrane with the 
membrane of the endosome on acidification of the vesicle to deliver the capsid and genome 
into the cytoplasm (163,176,178,180). Once in the cytoplasm, genomes bind to ribosomes 
as mRNA which is translated into a polyprotein, then cleaved into the four nonstructural 
early proteins described in last section (128,177,178).  The structural proteins are produced 
by protease cleavage of the late polyprotein that was produced from the 26S mRNA 
(176,178). Thereafter, envelope glycoproteins are translated, glycosylated, and cleaved 
from the remaining portion of the polyprotein to produce the E1, E2, and E3 glycoprotein 
spikes. The glycoproteins are processed by the normal cellular machinery in the 
endoplasmic reticulum and Golgi apparatus and are acetylated and acylated with long-
chain fatty acids (163,178,180, 181)  
The C proteins associate with the genomic RNA soon after their synthesis and form an 
icosahedral capsid. Once this step is completed, the capsid associates with portions of the 
membrane expressing the viral glycoproteins. The virus is then released by exocytosis or 







Figure 5. Replication and pathogenesis. Taken from 




Due to the lack of specificity of clinical presentation and specialized laboratories, the 
incidence of dengue and its economic costs are certainly underestimated (182). According 
the World Health Organization of the 100 million cases of dengue fever per year, up to 
500,000 develop dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) as 
the result of a secondary infection with other serotype (94,168-170) . 
Dengue virus infect both vertebrates and invertebrates. A full cycle occurs when the virus 
is transmitted by the invertebrate arthropod vector and amplified in a susceptible, 
immunologically naïve host (reservoir) that allows the reinfection of other arthropods 
(182,183). Birds and small mammals are the usual reservoir hosts but reptiles and 
amphibians can be too. (94,98,110,180)  
Increasing numbers of dengue cases occur coinciding with monsoon season and period of 
high vector prevalence. Surveillance of mosquitoes can help monitor the infection rates 
and the specific serotype also can predict an epidemia (100, 107). The disease occur during 
the summer months and rainy seasons, when the arthropods breed and the arboviruses are 
cycled among a host reservoir, an arthropod, and human hosts (107, 158). This cycle 
maintains and increases the amount of virus in the environment. In the winter, the vector is 
not present to maintain the virus but it can persist in arthropod larvae or eggs or in reptiles 




When humans travel into areas where the Aedes aegypti mosquito is present and the virus 
circulating, they are at risk of being infected. Pools of standing water, drainage ditches, and 
trash dumps in cities can also provide breeding grounds for the vector (98,110,111). An 
increase in the population of these mosquitoes also increases the risk for infection. These 
viruses include at least two forms of transmission, can be  maintained in a sylvatic or 
jungle cycle, in which monkeys are the natural hosts, and human can be accidentally 
infected if it is bitten by infected mosquitoes in the forest  in a sylvatic transmission cycle 
that has not been extensively studied  and also in an urban cycle which is the most 
common,  in which humans are the hosts. (98,107,110)  
2.7. Vaccines and immunity 
Despite some cross reactivity shown in dengue pathogenesis, there is no cross protection 
between the four serotypes and there is no specific treatment but the high human and 
economic costs as well as the absence of specific preventive measures show the need to 
develop a vaccine. (182)  
The challenges to develop a vaccine are; 1. absence of an animal model which is important 
for the preclinical analysis; 2. need to develop a live attenuated vaccine; 3.  existence of 4 
antigenically distinct serotypes (173,178,181); 4. immunologic risks related to antibody-
dependent enhancement (170); 5. absence of a well defined correlation between protection 
and preexisting vaccines; 6. complexity associated to industrial production of a tetravalent 
vaccine. (154,180) 
Introduction of dengue vaccination in the national immunization programs must be 
directed to regional epidemiological specificities and take into account the special features 
of each country.(172) Clinical studies with the most promising tetravalent vaccine were 
already started. In fact, Phase II clinical trials are now under way in children and adults in 
Mexico, Peru, and the Philippines. (111,140,184,185) 
Mice are often used as a small-animal model; however, the results are not always 
predictive of what will happen in humans.(94) The second animal model is the nonhuman 
primate, which demonstrate viremia but do not present clinical evidence so it is difficult to 
predict attenuation in humans. Despite all limitations, four types of dengue vaccines are in 
development including live attenuated vaccines, chimeric live attenuated vaccines, whole 
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virus inactivated or subunit vaccines, and nucleic acid–based vaccines (182) . Live 
attenuated vaccines (LAVs) can induce important humoral and cellular immune mimicking 
a natural infection but the viruses must be sufficiently attenuated, have low viremia, low 
reactogenicity, and high immunogenicity for prevent transmission by mosquitoes (186) . 
Chimeric Live Attenuated Vaccines are the most advanced developed for dengue/yellow 
fever. This vaccine uses the 17D yellow fever vaccine virus as its genetic backbone and 
replaces the yellow fever envelope (E) and prM genes with those from each of the four 
dengue viruses. This vaccine was shown to be attenuated, efficacious, safe, and highly 
unlikely to be transmitted by arthropod vectors (187) . Another chimeric live vaccine uses 
the PDK-53 DEN-2 vaccine candidate as a backbone. Similar to the concept of the yellow 
fever/dengue chimeric vaccine, the prM and E genes of DENV-2 are replaced with those of 
DENV-1, DENV-3, and DENV-4 (188) . A third chimeric live vaccine uses a DENV-4 
attenuated by a Δ30 deletion of the 3′-untranslated region as the backbone (189,190) . 
Whole-virus inactivated vaccines have two major advantages over live attenuated virus 
vaccines. First, it is not possible for inactivated vaccines to revert to a more pathogenic 
phenotype; second, induction of a balanced antibody response is easier to attain (190).  
DNA shuffling and screening technologies have been used to construct DNA expression 
vectors encoding the epitopes of the four dengue serotypes and show immunogenicity 
(191). DNA vaccines afford advantages in terms of ease of production, stability, and 
transport at room temperature, decreased likelihood of replication interference, and the 
possibility to vaccinate against multiple pathogens in a single vaccination. (190-192)  
2.8. Prevention and treatment 
Prevention requires control of vector mosquitoes; however it is difficult to implement and 
maintain (94,115). Management; otherwise, depends on symptomatic treatment of 
hemorrhagic complications and hypovolemic shock, especially in severe forms. (194) 
Despite of a lack of an specific antiviral therapy for dengue, antiviral therapy that blocks 
viral replication can clear viremia in a dose dependent manner, and reduce the spread of 
virus and the transmission. Several small-molecular inhibitors have been shown to target 
viral entry (195,196).  Currently, the most advanced targets for specific anti-dengue virus 
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therapy are the NS2B/NS3 protease and the NS5 RNAdependent RNA polymerase, E 
protein, NS3 helicase, and NS5 methyltransferase (196,198).  
Fluid replacement is the only recognized form of intervention for most patients with 
dengue haemorrhagic fever and dengue shock syndrome according to the individual 
dynamic evolution of the disease (117,129). Therapeutic regimens have been proposed 
according to World Health Organization's guidelines. Table 2 shows a summary of these 
guidelines. 94,199,200) 
Treatment schemes are organized in five levels according to dengue severity (115). 
Treatment is focused on adequate oral hydration and control of fever with antipyretics. 
Admission to hospital is required to enable fast and monitored hydration in the event of 
haemoconcentration or thrombocytopenia (level C), third space plasma leakage (level D), 
dengue shock syndrome with pulse pressure <10 mm Hg (level E). (94,199,200) 
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Table 2. Treatment guidelines according to level of dengue severity. FROM: Teixeira MG, Barreto ML 
Diagnosis and management of dengue BMJ. 2009 Nov 18;339:b4338 
Features Treatment 
Level A 
Patient with signs and symptoms of dengue fever Oral hydration 
 
No warning signs Antipyretics and analgesics* 
 
Level B 
Patient with signs and symptoms of dengue fever Vigorous oral hydration 
 
Spontaneous haemorrhagic manifestations or positive 
tourniquet test; absence of other warning signs 
Antipyretics and analgesics* 
Level C 
Patient with signs and symptoms of dengue fever 
 
 
Keep the patient under strict 
observation at a health care unit with 
enhanced oral hydration 
 
Raised packed cell volume (until 10% above baseline 
value) with or without thrombocytopenia (50×106/l to 
100 000×106/l); with or without other warning signs  
 
Antipyretics and analgesics* 
 
Level D 
Haemoconcentration: raised packed cell volume (>10% 
above baseline value). In the absence of this 
information consider the following values for increased 
haemoconcentrations—children, >42%; women, >44%; 
men, >50%; with or without other warning signs 
Intravenous hydration with crystalloid 
solution and plasma expander in a 
healthcare unit under medical 
supervision for at least 24 hours; 
provide sufficient fluids to prevent 
shock; antipyretics and analgesics*; 
clinical re-evaluation and measurement 
of packed cell volume after hydration 
 
Level E 
Shock (pulse pressure <10 mm Hg) Ideally in an intensive healthcare unit; 
intravenous colloid solution (hydroxy 
ethyl starch 6%, molecular weight 
200,000; Dextran 70) is mandatory 
Haemorrhagic manifestations present or absent Transfusion of fresh whole blood or 
fresh frozen plasma in case of severe 
gastrointestinal bleeding 
Essential laboratory tests: complete blood count, determination of serum albumin, chest radiography. 
Other tests might be needed: glucose, urea, creatinine, electrolytes, serum aspartate aminotransferase and 
serum alanine aminotransferase, blood gas analysis, and ultrasonography of abdomen and chest. 
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Antecedentes del estudio: Durante los periodos lluviosos los barrios marginales de 
Guayaquil-Ecuador han sido constantemente afectados por leptospirosis y dengue, dos 
enfermedades que presentan una sintomatología muy similar. El propósito del presente 
trabajo fue investigar la frecuencia de leptospirosis en la población de los barrios 
marginales de Guayaquil y el grado de dificultad que existe para distinguir clínicamente 
leptospirosis de dengue.  
Materiales y Métodos: Muestras de sangre de pacientes febriles provenientes de los 
barrios pobres de  Guayaquil fueron colectadas durante la estación lluviosa del año 2008. 
Las muestras se sometieron a análisis de ELISA IgM para dengue y leptospirosis. 
Adicionalmente se obtuvieron datos retrospectivos (2003-2007)  de historias clínicas de 
pacientes  que acudieron a uno de los hospitales públicos más grandes de Guayaquil.  
Resultados: De un total de 135 pacientes febriles, 15 (11.1%) fueron positivos a 
leptospirosis por ELISA, 36 (26.7%) fueron positivos a dengue, 3 (2.2 %) fueron positivos 
a ambos patógenos y 81 (60%) fueron negativas para los dos. Según el diagnóstico clínico 
los casos febriles se clasificaron 68.1% como dengue,  20.7% como leptospirosis, y  9.6 % 
como malaria y 1.5% como otro. Sin embargo, 60,0% de los pacientes diagnosticados 
clínicamente como dengue tuvieron  anticuerpos contra Leptospira y no para dengue y 
25.0% pacientes diagnosticados como leptospirosis tuvieron anticuerpos contra el virus de 
dengue y no para Leptospira. Adicionalmente, los archivos hospitalarios (2003-2007) 
indicaron que 72.8% de los pacientes diagnosticados clínicamente como dengue tuvieron 
anticuerpos contra Leptospira y carecían de anticuerpos contra virus de dengue.   
Conclusiones: Los resultados sugieren que dengue y leptospirosis son dos enfermedades 
que ocurren con frecuencia y simultáneamente en los meses lluviosos en la ciudad de 
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Guayaquil.  También sugiere que ambas enfermedades son frecuentemente identificadas 
erróneamente lo que representa un problema grave de salud pública pues ambas 





Background:  Leptospirosis and dengue fever are two diseases causing very similar 
symptoms in Guayaquil during rainy seasons.  The purpose of this study was to assess the 
frequency of leptospirosis and dengue during a rainy season and the difficulty to 
distinguish clinically both diseases. 
Methods: Blood samples from febrile patients from poor neighborhoods in Guayaquil 
were obtained during the rainy season of 2008 and analyzed by IgM ELISA for dengue and 
leptospirosis. Additionally, retrospective data (2003-2007) from febrile patients who 
attended one of largest public hospitals in Guayaquil were obtained.  
 Results: From 135 febrile patients samples, 15 (11.1%) were positive to leptospiral 
ELISA, 36 (26,7%) were positive for dengue, 3 (2.2%) were positive for both pathogens 
and 81 (60%) were negative to both.  Based on clinical diagnosis, febrile cases were 
classified 68.1% as Dengue, 20.7% as leptospirosis, 9.6% as malaria, and 1.5% as other. 
However 60.0% of patients clinically diagnosed as dengue had antibodies against 
Leptospira but not for dengue virus and 25.0% patients diagnosed as leptospirosis had 
antibodies for dengue but not for Leptospira. In addition the hospital archives indicated 
that 72.8% of the patients diagnosed clinically as dengue had antibodies to Leptospira and 
lacked of antibodies to dengue.  
Conclusions: The results suggest that dengue fever and leptospirosis are two diseases that 
occur frequently and simultaneously during the rainy months in Guayaquil. This study also 
suggests that both diseases are often misidentified which is a public health problem 





Leptospirosis, a zoonosis that occurs throughout the world, especially in tropical climates 
(1), is caused by any of the eleven pathogenic species of the spirochete Leptospira (2) 
which causes a spectrum of disease ranging from flu-like to life threatening hemorrhagic 
syndromes (1,3-8). In developing countries the disease causes a significant health burden 
in slums and rural populations during rainy seasons (3-6,9,10). Although leptospirosis is 
classically associated to individuals working in close proximity to domestic and wild 
animals (11,12) recent reports show increasing numbers of cases in people exposed to fresh 
water in urban settings or during recreational activities (13-16). Urine from animal 
reservoirs (dogs, pigs, rats, etc) is removed from soil by rainwater and carried by flooding 
water to rivers and puddles were humans and other animals get infected by skin or mucosal 
exposure (3,4, 5,16,17,18). Urban slums are especially vulnerable to this infection due to 
deficient sewage systems (1,3-5,12), poor drainage and large number of animal carriers 
(especially rats and dogs) (18-24).  A recent report suggests that leptospirosis is the most 
frequent infection in febrile patients inhabiting tropical towns in Ecuador (42).  Outbreaks 
of leptospirosis have been reported in Guayaquil since the beginning of the twentieth 
century and the most important recorded occurred during the winter and spring 1997-1998 
which was associated with 11.8% mortality, high hospitalization rates and 12% 
seroprevalence after the outbreak (25). 
In the Americas, dengue was first recognized in the 18th century, and largely eradicated 
from the continent in the 1950-60’s.  Re-introduction occurred after intensive top-down 
approaches to eradicate vectors ceased  in the 1970’s and  soon dengue spread  in the 
Caribbean and Central America and detected in Ecuador in 1988 (39). Dengue viruses are 
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transmitted by mosquitoes of the genus Aedes, which are widespread in tropical and 
subtropical climates (26,27). This illness tends to increase during rainy seasons due to the 
presence of clean water collections favoring the multiplication of mosquitoes (28-30). 
There are four distinct serotypes of dengue arbovirus: DENV1, DENV2, DENV3, DENV4 
(31,32).  Similar to leptospirosis, dengue viruses can cause symptoms ranging from the 
classical self-limiting flu-like disease to a severe, potentially fatal hemorrhagic syndrome 
known as dengue shock syndrome (29, 32, 33).  Dengue is also an emerging disease 
because of the recent geographic expansion of the vector especially in Western Pacific 
Regions (32,34).  The combination of multiple factors have contributed to the 
dissemination do the disease including population growth associated with rapid 
uncontrolled urbanization, increased population mobility, demographic changes, poor 
vector control, genetic changes in circulating or introduced viruses, and modulating 
climatic factors (5,6,35-37).   
Leptospirosis and dengue fever are two diseases that co-occur in rainy seasons in tropical 
cities such as Guayaquil and share many symptomatic features (40,41). In fact, both 
diseases are part of what is called “acute undifferentiated febrile illness” (AUFI) which is 
common in tropical regions of the developing world (42). The purpose of this study was to 
assess the burden of leptospirosis in the slums of Guayaquil and its possible confusion with 
other tropical diseases such as dengue (38, 40-45). For this purpose we analyzed the 
presence of anti-leptospira and anti-dengue virus IgM antibodies in blood form febrile 
patients inhabiting a slum of Guayaquil during rainy season 2008, additionally we did a 
retrospective review of the clinical archives of the main infectious diseases public hospital 




MATERIALS AND METHODS 
Study site and population 
The study was conducted in the Bastion Popular community (Figure 1A) which is situated 
in the north part of Guayaquil, in a community with over 90,000 inhabitants .  It is a region 
with several valleys and it is a densely-populated slum (Figure 1B). In total, 3,70% of the 
population of Guayaquil reside in this area with significant  levels of poverty. Subjects 
were enrolled into the study during the rainy season between December 2007 and May 
2008  
Household survey 
The study team (brigades) of community health workers, nurses and physicians conducted 
interviews during house visits and administered a standardized questionnaire (Appendix 2)   
to obtain information on demographic and socioeconomic indicators, employment and 
occupation, and exposures to sources of environmental contamination and potential 
reservoirs in the household and workplace. Subjects were asked to report the highest 
number of rats sighted within the household property and the site of work-related activities. 
The study team surveyed the area within the household to determine the presence of dogs, 
cats and chickens. The survey was provided by Albert Ko as far it was previously used in 
Brazil (61) An informed consent (Appendix 4) was developed and all patients enrolled 
voluntarily and were provided with written consent forms. All protocols were approved by  
Universidad San Francisco de Quito bioethics committee. All data collected was 





Dried blood spots 
Febrile patients, residing at the Bastión Popular areas of Guayaquil, were identified by the 
health brigades of the Ecuadorian Ministry of Health and asked to donate a drop of blood 
following standardized protocols (47) after voluntarily accepting to be part of the study and 
filling out the consent form and the household survey.     
 Blood extraction, transportation and sample storage is indicated in Appendix 6. To assure 
the correct application of protocols, every week the process was evaluated in a meeting 
with the health personnel during the time of the study. 
Sample exclusion criteria were patients showing diarrheic symptoms, common cold 
symptoms, and patients younger than 4 years of age. The first were defined based on 
characteristics of other well defined syndromes and the last considering that children less 
than 4 years do not work or study. The main inclusion criteria was the clinical evidence of 
fever of unknown origin, also secondary inclusion criteria included  living or working at 
Bastion Popular, and symptoms such as chills, myalgia, cephalea or Icterico-febrile 
syndrome. 
Blood drops were extracted by the health personnel, subsequently  samples were allowed 
to dry for at least 4 hours, wrapped with waxed paper and stored with silica gel for 
transportation until placed inside plastic bags that were sealed and stored for up to two 
weeks at room temperature. Finally samples were stored at -20° at the Microbiology lab at 
San Francisco de Quito University until processing (48-51). The samples were labeled with 
an arbitrary code corresponding to the same code assigned at the survey avoiding the use 
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the patient´s names for ethical reasons. All samples that were not treated following the 
established standardized operating procedures were discarded and a new sample obtained.  
. 
Serological Tests 
A modified procedure for an ELISA kit for both leptospirosis and dengue (PanBio Pty. 
Ltd, Australia) was used. A 6 mm punch of the blood spot in filter paper was eluted in 150 
μl of PBS and 29 µl of the eluted serum was placed in a well containing 71µl of serum 
diluent reagent (49,50).  Plates were covered and incubated at 37 °C for 30 minutes, then 
washed with washing buffer 6 times, and allowed to dry. The rest of the procedure was 
performed following the instructions provided by the manufacturer. 
A microagglutination test was performed on leptospira positive sera as described (54) 
however, we used the corresponding sera elution correction in order to reach 1:100 sera 
dilution (54,55).   
Retrospective Hospital Data  
Partial data from leptospirosis suspected patients (LSP), that attended the Hospital de 
Infectología José Daniel Rodríguez Maridueña in Guayaquil during the last 5 years (2003-
2008) was obtained.   Data was analyzed based on a modification of the interview field 
form to obtain information on the following. Demographic and socioeconomic indicators, 
employment and occupation, exposures to sources of environmental contamination and 
potential reservoirs in the household, workplace, evidence in the clinical record listed 
prepared by the physician who reported the case of any of these risk factors listed above. 
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Names of patients were omitted and were only recopilated from cases reported with one of 
the suspected diagnosis of leptospirosis. 
The data collection was carried out separately and independently of the field study. 
 
Statistical and Epidemiological Analysis  
Analysis was performed using EpiInfo version 3.4.3 and StatView packages.  
RESULTS 
All inhabitants at Bastion Popular were eligible residents at the slum community, 135 were 
enrolled in the study. In this group we had a higher proportion of females (64.4%) than 
males (34.8%) and a mean age of 25,4 years (SD: 16,63; 4-78 years old).  Among the 
subjects, 51(37,8)% had their houses constructed over water, and the frequency of work 
and residence in the same place was 36,3%, observing  a high frequency of subjects that 
reported the activity of housewife or householder as principal work. Frequencies of 
household risk factors, work places association are listed on Table 1.  
From 135 blood samples obtained from febrile patients at Bastión popular and close to 
Pascuales, the calculated prevalence was 11.1% (95% CI 6,4–17,7) and 26,7% (95% CI 
19,4–35). for Leptospira and dengue antibodies respectively.  Three samples (2.2%; 95% 
CI 0,5-6,4) were positive for both antigens and 81 (60%; 95% CI  51,2 – 68,3) were 
negative to both by IgM ELISA procedure. Dengue fever was clinically diagnosed in 
68.1% of the febrile patients, leptospirosis in 20.7%, malaria 9.6%, and other 1.5% (Table 
2). Clinical diagnosis of these patients showed little correspondence to their serologic 
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reactivity; 9 patients (60%) clinically diagnosed as having dengue fever showed positive 
IgM titers to Leptospira and no reactivity to dengue. Conversely 25% of patients clinically 
diagnosed as leptospirosis cases had positive IgM titers to dengue virus and did not show 
any reactivity to the leptospiral test.  Leptospira ELISA positive sera showed highest MAT 
titers to serovar Patoc in 7 sera, serovar Panama in 3 sera, serovar Pomona in 3 sera, 
serovar Icterohaemorragiae in 2 sera, serovar Tarassovi in 2 sera and serovar Autumnalis 
in 1 serum. 
Prevalence was adjusted for the age and gender distribution of enrolled subjects in the 
study. Prevalence was highest among children and adults; 33,3% for 5–14 years of age and  
27.8% for 25-34 years of age (95% CI 13,3– 59 and 95% CI 9,7– 53,5, respectively) 
(Table 1). However, 16,7% (95% CI 3,6–41,4) of 15-24  and 35 – 44  years of age had 
evidence for leptospirosis. The prevalence of dengue was highest among adolescents and 
adults; in fact,  25,6% for 15–24 years of age and  30,8% for 35-44 years of age (95% CI 
13– 42,1 and 95% CI 17– 47,6, respectively ).  
The prevalence of Leptospira was higher in females than males (7.6 versus 3.8%, 
respectively; OR 2,6 95%; CI 0,65–10.38 p= 0,09); and the prevalence of  dengue was 
higher in females than males (20,5 versus 6.8%, respectively; OR 3,16; 95% CI 1.19–8,38 
p=0,01). 
High frequencies of related jobs are reported on cases. In fact, on leptospirosis cases, 
housewives and students are more frequent (33,3% and 38,9%, respectively) and on 
Dengue cases, housewives (53,8%) are the most common affected (Figure 1 and  2). 
There isn´t significant risk association with the disease. 
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The main risk factors associated to patients with sera positive to leptospirosis were having 
their home over water, presence of garbage, contaminated drain water at home, sewer 
contact and evidence of rats at home;  moreover, two relevant and statistic significant risk 
factors are the evidence of rats walking at daylight, and home flooding (Table 3), whereas 
risk factor associated to sera positive to dengue ELISA were garbage close to home, 
proximity to drain water and sewer, home flooding and street flooding; however, none of 
these show statistic relevance. 
Subjects who resided in houses with flooding water had a 4,085 times (95% CI 1,006-
16,57) increased risk for having anti-Leptospira antibodies than those who resided in 
houses over dry properties. People living in houses with rats walking during the day had 5 
times (95% CI 1,06-23,46) more risk for leptospirosis. Sighting of two or more rats was a 
sign for rat infestation, and is a significant reservoir-associated risk factor for the 
household. 
Having pets and reporting sighting rats at the workplace environment was not associated to 
risk according to the analyzed data. Open rainwater drainage structures and garbage 
deposits were distributed throughout the study area; yet sewers were very infrequent at the 
slum. (Figure 3).  
The main symptoms associated to leptospirosis ELISA positive patients at community 
were fever, headache, join and muscular pain, respiratory difficulties, jaundice, oliguria, 
and conjunctiva suffusion (Table 3). Most frequent symptoms associated to dengue ELISA 
positive sera were fever, headache, joint and muscular pain, respiratory difficulties, 
jaundice, conjunctiva suffusion. Hospital records (2003-2007) showed similar symptoms 
for leptospirosis and dengue: fever, headache, generalized muscle pain, jaundice and 
conjunctiva suffusion (Data not Shown) 
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Archival clinical chart data from the hospital during the period of 2003 to 2007 showed 
that from a total of 107 records recovered, the number of suspected dengue cases was 59 
and the number of suspected leptospirosis cases was 29.  Inconsistencies between clinical 
presumptive diagnosis and laboratory results attached to clinical records was also evident 
in these records; 72.88% of patients clinically diagnosed as dengue showed positive 
serology to Leptospira and no reactivity to dengue virus and 17.2% of patients clinically 
diagnosed as leptospirosis had positive serology to dengue virus and no reactivity to 
Leptospira,   25.4% of patients clinically diagnosed as dengue had positive sera for both, 
Leptospira and dengue virus, 1 case reported as dengue fever, and 5 reported as 
leptospirosis were negative for both ELISA tests.  
DISCUSSION  
The data presented here suggests that dengue and leptospirosis are two very common 
infectious diseases that co-occur during rainy seasons in the slums of Guayaquil, and 
dengue fever was the most frequent clinical diagnosis of febrile presentations during the 
rainy season of 2008.  Archival data obtained from one of the largest public hospitals also 
suggests  that dengue and leptospirosis were the most frequent causes of febrile disease 
(including malaria and hepatitis) from 2003 to 2007 (data not shown).   
Our results indicate that 68.5% of the febrile cases were misdiagnosed as either 
leptospirosis or dengue fever. The discrepancy between the clinical diagnosis and the 
serology may reflect the similarity of the clinical manifestations of these two diseases 
(Table 2), as shown in other studies (61-63). 
Misdiagnosis of these two diseases is an important public health concern because the two 
diseases require different therapeutic approaches. Unlike with dengue fever, clinical 
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complications of leptospirosis can be easily avoided using antibiotics (3,17,23,38,56,57).  
Complications due to dengue can be avoided by early support intervention and hospital 
referral of cases with alarming signs and symptoms (58).  Both diseases share some risk 
factors which are associated to low income communities in tropical cities and rainy 
seasons (accumulation of water and deficient drainage) (60-63).These conditions are likely 
to worsen due to global warming (24,25,27,36,58) and rapidly expanding slums (30-33). A 
previous study on slum community performed in Salvador showed a 12% prevalence rate 
of anti –Leptospira antibodies in general population, and other study from Brazil slums 
showed a 15% (61,65) in general population too using MAT as diagnostic tool(61). In this 
community-based survey at slums of Guayaquil, we found that 11,1% of all febrile cases 
had  IgM against  Leptospira .. 
In conclusion, our findings, suggest that differences between dengue and leptospirosis are 
not so evident for clinicians, and dengue was the most frequent clinical diagnosis among 
the population enrolled. 
Our study has limitations. Anti-Leptospira IgM antibodies can persist for years after initial 
exposure (19) and IgM antibodies may remain detectable for at least as long as 3 months 
after symptom onset (57). It is therefore difficult to differentiate between current and past 
infections. In fact, it is difficult to attribute the acute symptoms reported to an acute 
leptospirosis infection or to a more recent infection of different etiology characterized as 
an AUFI (42). Therefore, it should have done a seroconversion test to corroborate that the 
leptospirosis infections were recent (63). 
A second limitation is the reported low sensitivity of ELISA test (<25%) when applied to 
acute-phase specimens (64,67). It is therefore likely that the rates of leptospiral infection in 
our study population are higher than reported. Also, the study was performed through 
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home visits so the population studied reflected household characteristics; however, people 
that were working far from their homes at the same time of interview weren´t included. 
A third potential limitation is that we weren’t able to  calculated predictive values for the 
modification of the ELISA protocol using, however  dried blood spots have been used with 
high sensitivity and specificity for prevalence studies, outbreak surveillance and population  
screening for other diseases   (47,49).  
Since the study was performed in a single community our findings may not be 
generalizable to other slum settings. However, a large proportion of the world’s slum 
population resides in tropical climates similar to this slum and reported similar conditions 
(Figure 3).(61,62,63,65) Then our findings may therefore be relevant to other slum 
communities where leptospirosis and Dengue are endemic.  
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TABLES AND FIGURES 




(n=135)  Positives IgM ELISA  Negatives 








 Yes  Yes  Yes  Yes 







05 to 14 44 32,6  6 33,3  4 10,3  34 42,0 
15 to 24 29 21,5  3 16,7  10 25,6  16 19,8 
25 to 34 23 17,0  5 27,8  7 17,9  12 14,8 
35 to 44 21 15,6  3 16,7  12 30,8  8 9,9 
45 and over 18 13,3  1 5,6  6 15,4  11 13,6 
Gender 






 Male 48 35,6  5 27,8  9 23,1  34 41,9 
Household factors            
Home over water 51 37,8  5 27,8  14 35,9  34 42 
Garbage at home 95 70,4  12 66,7  26 66,7  60 74,1 
Inundation 67 49,6  5 27,8  14 35,9  49 60,5 
Rats proximity 104 77,0  11 61,1  32 82,1  63 77,8 
Dogs 86 63,7  9 50,0  27 69,2  52 64,2 
Cats 57 42,2  10 55,6  13 33,3  34 42,0 
Chicken 58 43  10 55,6  13 33,3  36 44,4 
Work related exposures            
Contact with contaminated 
environment a 
55 40,7  8 44,4  19 48,7  30 22,2 
Rats 16 11,8  1 5,6  4 10,3  11 13,6 
a Reported exposure to mud, garbage, flooding water or sewage water in the workplace. 
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FIGURE 1.  Frequency of distribution of work in leptospirosis cases. 
 















Photographs of the typical environment at the community study site, which shows the proximity of 




TABLE 2.  Clinical diagnosis compared to serologic results.  Numbers correspond to febrile patients 
from slums in Guayaquil diagnosed clinically and by ELISA. 
 
Clinical Diagnosis 
 Number of ELISA Positive Sera  
  Dengue  Leptospira  Both  None 
Leptospirosis   9 4  1 14  
Dengue Fever  23 9  2 58  
Malaria   4 2  0 7  
Other   0  0  0  2  





TABLE 3. Clinical manifestations in patients with positive serology leptospirosis and dengue. Data 




SYMPTOMS  Positive IgM  ELISA  
Leptospira   Dengue virus 
Fever  100.0 100 
Headache 97.4 97,4 
Join and muscular pain 94.5 92,3 
Respiratory difficulties 61.5 61,5 
Jaundice  56.4 53,8 
Oliguria (patient’s perception) 38.5 28,2 
Conjunctiva suffusion 33.6 46,1 
Haemoptysis 10.3 10,2 
Calf pain 5.1 ------ 







TABLE 4. Risk factors. Data obtained from interview forms collected from febrile patients which 
report positive antibodies against Leptospira and/or dengue virus in the slums of Guayaquil. Values 














Positive IgM  ELISA 




95% CI     
(min-max) 
Home over water 2,08 (0,51-8,33) 1,69 (0,68-4,2) 
Garbage 1,75 (0,39-7,7) 1,27 (0,48-3,3) 
Drain Water at home  3,5 (0,8-14,8) 1,67 (0,68–4,11) 
Drain Water  at work  1 (0,05-17,32) 0,24 (0,04-1,27) 
Sewer contact  2,12 (0,17-25,77) 1,76 (0,39-7,9) 
Home inundation 4,085 (1,006-16,57) 2,31 (0,9-5,7) 
Street inundation 0,43 (0,06-2,76) 1,37 (0,45-4,14) 
Rats at home 5,09 (0,88-29,2) 0,84 (0,27-2,61) 




5. ADENDUM  
5.1  LEPTOSPIRAL CULTURES. 
The bacteria were cultivated at 30°C and the serovars used as antigens were the 
recommended on standard methods of the Royal Tropical Institute. The Leptospira´s 
culture had a cell count of 107 or 108, determined on a Petroff - Hausser chamber count in a 
home prepared supplement for EMJH liquid medium. (201) 
5.2 WATER SAMPLES COLLECTION 
The water samples that were positive at PCR, were collected at Bastión Popular, Block 1B 
and at “Las Lojas” which is the place with more confirmed cases of leptospirosis.  
5.3 DNA ISOLATION. 
Extraction of DNA from water samples were performed and compared with a DNA extract 
from a strain cultured (L. autumnalis), approximately 106–108 cells from 1 ml of a 7-day 
Leptospira culture in EMJH was used as positive control. Subsequently, it was performed 
CTAB DNA extraction Protocol. The samples were added 700 ul of CTAB (2% (w/v) 
CTAB, 1.4M NaCl, 20mM EDTA, pH 8.0) for 2 hours at 65° C°, then added 700 ul of 
chloroform-isoamyl alcohol (24:1) and centrifuged at 12.000 RPM for 5 minutes to 
separate DNA from other particles in solution. DNA isolated was precipitated overnight 
using 3M Sodium Acetate (pH 5.0), and 100% ethanol. Finally, after 24 hours the solution 
was centrifuged at 14000 RPM for 10 minutes to obtain a DNA pellet which was washed 
with 70% ethanol and suspended  in TE buffer (10mM TRIS – HCl, pH 8.0; 0.1mM 
EDTA). DNA was stored at -20°C. 
5.4 PCR PROTOCOL FOR DETECTION OF LEPTOSPIRAL DNA IN 
FLOODING WATER 
AB/CD primers were used to amplify standard Leptospira´s sequence. Primer A, 5´-
GGCGGCGCGTCTITAAACATG-3' and B, 5'-TTCCCCCCATTGAGCAAGATT-3', 
which correspond to nucleotides 38 to 57 and 348 to 368 in the primary structure of the L. 
interrogans rrs (16S) gene, respectively and primers C, 5'-
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CAAGTCAAGCGGAGTAGCAA-3' and D, 5'-CTTAACCTGCTGCCTCCCGTA-3', 
which correspond to nucleotides 58 to 77 and 328 to 347, respectively. PCR reactants and 
protocol was performed as described at Merien et al. 1992. (49,202)  
In order to probe if this isolated DNA from water samples was from a pathogenic 
leptospiral serovar, we performed a more specific PCR, with primers G1 and G2; G1, 5´-
CTGAATCGCTGTATAAAAGT-3´ and G2, 5´-GGAAAACAAATGGTCGGAAG-3´, 
derived from sequences obtained from a genomic library of L. interrogans serovar 
icterohaemorrhagiae were used to differentiate pathogens from environmental strains. 
(203) 
We performed a PCR with DNA from cultured Leptospira to probe that the protocol was 
correct 
6. RESULTS OF DETECTION OF LEPTOSPIRAL DNA IN 
FLOODING WATER  
A PCR with primers  A, 5´-GGCGGCGCGTCTITAAACATG-3'; B, 5'-
TTCCCCCCATTGAGCAAGATT-3'; C, 5'-CAAGTCAAGCGGAGTAGCAA-3'; and D, 
5'-CTTAACCTGCTGCCTCCCGTA-3' was performed demonstrating evidence of  
leptospiral DNA in environment. However, only two water samples amplified the DNA 
(Figure 6, arrows), none amplified with C-D primers (not shown). 
 
     C+ = L. autumnalis.DNA 




Primers G1 and G2 show no amplification of any sample. Neither those that were positive 
to A-B primers (Figure 7). The PCR with DNA from cultured leptospira probed that the 
protocol was well done (Figure 8). Then, none water sample seems to be positive for 
pathogenic strain. 
 C+ = L. icterohaemorragiae DNA 
Control= L. Copenhageni  DNA 
Figure 5. PCR. . PCR performed with primers G1 and G2 
 
 
Figure 6. PCR. . PCR performed with primers G1 and G2. C- (No-DNA), C+ (DNA from L. 
icterohaemorragiae previously probed). NP (non pathogenic leptospira). P (pathogenic Leptospira P1. L 
interrogans¸ P2 Leptospira autumnalis, P3 Leptospira Copenhageni) 
Ladder     C+   1       2      3     4       5      6      7      8     9     10    11    12   13    14    15    16    C-   Control    




7. SUPPLEMENTARY INFORMATION 
 
7.1 ELISA Absorbances  
This table shows the distribution of the analysis of the samples, the localization in the 
ELISA’s plate of the each valid sample 
 
This table shows the index value that each sample get in the analysis of the absorbance. 
 
This table shows the Panbio units of each sample. 
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7.2 Appendix 1 
HOJA INFORMATIVA 
Burden of Leptospirosis in the Slums of Guayaquil, 
Presencia de Leptospirosis en Barrios marginales de Guayaquil. 
 
1) Introducción: 
Leptospirosis, es una de las enfermedades adquiridas desde animales más comunes del mundo.  
Se puede presentar como una gripe simple o también como un problema hemorrágico que puede 
llevar a la muerte. El microbio vive en los riñones de los animales que lo portan como perros y 
ratas, sin que estos presenten enfermedad. Lo eliminan en la orina, la cual tras la lluvia, es llevada 
hacia ríos o reservorios de agua donde el microbio puede seguir viviendo por mucho tiempo 
entonces las personas que tienen contacto con el agua de estos sitios pueden contagiarse (NO 
SIEMPRE),  es posible que exista este microbio en estas zonas de Guayaquil por estar sus casas 
construidas sobre sitios donde se encuentra naturalmente agua. 
Existen casos confirmados de hemorragia por leptospirosis en Guayaquil que puede ser  
confundida con fiebre amarilla, dengue o malaria. Sin embargo no se le ha puesto mucha 
importancia, a pesar de existir posibilidades de contagio, como inundaciones, o falta de buenos 
drenajes cuando hay épocas de lluvia, aumentando la cantidad de agua donde podría estar 
viviendo el microbio, ya que existen animales callejeros cuyas orinas pueden estar infectadas. 
2) Justificación y Objetivos de la Investigación:  
Existe un gran número de cuadros clínicos asociados a leptospirosis en Guayaquil que es 
ampliamente mal reconocida, o mal diagnosticada, debido a que no es un problema de reporte 
obligatorio a nivel Ministerial, no hay un diagnostico relevante y la presentación clínica puede no 
ser reconocida y confundida por los clínicos. 
 
3) Metodología empleada 
 a) Pacientes que se considere pueden presentar Leptospirosis de los barrios 
marginales de Guayaquil, así como del Hospital de Infectología. 
 b) El estudio dura aproximadamente 5 meses, a partir de Diciembre del 2007 hasta 
Abril del 2008 
 c) Se recolectarán muestras de gotas de sangre mediante una lanceta, haciendo 




 d) Es un estudio, descriptivo, epidemiológico, que busca encontrar la prevalencia, e 
incidencia de la patología. 
    
4) Procedimientos y su propósito: 
 a) Entrevistas 
 b) Cuestionarios 
 c) Muestras para el laboratorio, extracción de muestras de sangre por punción en el 
dedo de la mano, para el análisis de la presencia del patógeno. 
 d) Muestras complementarias en caso de ser necesarias con autorización y 
consentimiento informado 
 
5) Incomodidades y riesgos derivados del estudio: 
 a) Es un procedimiento inocuo, solo conlleva la punción del pulpejo del dedo, sin 
mayor, relevancia o posibles complicaciones del procedimiento 
 b) No existe tampoco, la posibilidad del uso de los datos personales de cada paciente 
para otras circunstancias, excepto que para control epidemiológico. 
   
6) Beneficios derivados del estudio:  
 a) No existen beneficios individuales, el beneficio seria colectivo, pues si  la sospecha 
de que existe mayor cantidad de casos de leptospira que lo que se diagnostica, se podría 
implementar un sistema de vigilancia epidemiológica con el fin de reducir los casos. 
 
7) Privacidad y Confidencialidad 
 a) Todos los datos proporcionados serán manejados con total confidencialidad por 
las personas implicadas en el estudio. 
 
8)  Participación voluntaria y Retiro del Estudio  
 a). Es  voluntaria su participación, así como la posibilidad de retirarse del estudio en 




 b). Todos los hallazgos nuevos que se descubran durante el transcurso del estudio, 
que pudieran afectar su deseo de seguir participando, deberán ser comunicados al sujeto en 
investigación. 
 c). El paciente tiene todo el derecho de negarse a la participación si el encuestador o 







7.3  Appendix 2 
Impacto de la  Leptospirosis en Barrios Marginales de  Guayaquil 
Fecha de entrevista mes dia año 




II. PRESENTACION CLINICA  
 
  
2.1 Cuántos dias ha estado enfermo (a)? 
2.2 Febre: 
Si   No    
 
Temperatura 
2.3 Tomó antibiótico? 
Si   No   No sabe  
 
2.4 Ictericia: 
Si   No   
 
2.5 Sufusión Conjuntival: 
Si   No   
 
2.6 Dificultad respiratoria: 
1.1 Nombre del paciente 
1.2 Edad: 
1.3 Fecha de nacimento: mes Dia año 
1.4 Sexo: 
Masculino   Femenino   
 




Si   No   
 
2.7 Hemoptisis: 
Si   No   
 
2.8 Frecuencia Respiratoria: 
2.9 Oliguria 
Si   No   No sabe  
 
2.10 Dolor muscular/articular 
Si   No   
 
 
Localización del dolor 
2.11 Dolor de cabeza 
Si   No   
 
2.12 De acuerdo alos síntomas usted sospecha de: 
 
Dengue   Leptospirosis               Malaria  
 
  
III. Factores de riesgo: 
  
3.1 Su casa esta construída sobre agua?: 




















a. Alcantarilla desagües  Si   No   
        
b. Constrcuccion  Si   No   
        
c. Vendedor ambulante  Si   No   
        
d. Agricultura/ganaderia  Si   No   
        
e. Mecanico  Si   No   
        
f. estudia  Si   No   
 
3.3 
Trabaja en el  barrio que vive?                                              
Si   No   
 
3.4 
DURANTE LAS ULTIMAS TRES SEMANAS
 
 USTED ESTUVO :  
EN CONTACTO CON LODO 
       
a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o botas? Si   No   
3.5 








a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       





EN CONTACTO CON AGUA DE INUNDACION 
  
 a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o botas? Si   No   
 
3.7 
EN CONTACTO CON AGUA DE ALCANTARILLA 
 
 
       
a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o botas? Si   No   
3.8 







a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o botas? Si   No   
3.9 
Se inundó su casa durante la lluvia? 
Si   No   
 
3.10 
Se inundó la calle cercana a su casa por la lluvia? 
Si   No   
 
3.11 
Se inundó su lugar de trabajo 






Ha visto ratas ultimamente? 
  a. Cerca de la casa  Si   No  
       
b. Cerca del trabajo  Si   No  
3.13 
 
Cuantas ratas ha visto juntas? 
 
a. Cerca de la casa?   
   
b. En el trabajo?   
3.14 
 
Ha visto ratas caminando durante el día? 
   
                   a. Cerca de la casa  Si   No  
       
b. En el trabajo  Si   No  
3.15 
Tienen perro en la casa o los perros de su vecino visitan su casa? 
No    Si   
 
3.16 
Tienen gato en casa? 
No    Si   
 
3.17 
Tiene gallinas en casa? 
No    Si   
 
3.18 





7.4 Appendix 3 
INSTRUCTIVO PARA LLENAR LA ENCUESTA 
I. CAPACITACIÓN DE ENCUESTADORES. 
El personal destinado para las encuestas, será escogido mediante un proceso previo de 
selección. El proceso de capacitación será realizado mediante presentaciones y 
demostraciones prácticas de la encuesta. Preferentemente sería llenado en el momento 
de la Anamnesis. 
La guía será entregada a los encuestadores con el fin de facilitar el proceso de llenado 






Su función será la de llenar el cuestionario adjunto, además de recolectar las  
muestras de gota seca de sangre utilizando el procedimiento detallado. 
Se debe recordar que las encuestas están encaminadas a recolectar información sobre 
los factores de riesgo que nos inviten a sospechar en el diagnóstico de Leptospirosis, por 
tal razón es de gran importancia que se llene correctamente el cuestionario. 
GUIA 
NO olvidar poner el número correspondiente a la encuesta y que 








El primer campo, debe ser llenado de manera OBLIGATORIA,
Fecha de entrevista 
  puesto que esta 
información nos permitirá aclarar cualquier duda en cuanto a quien y donde se realizó la 
encuesta. 
mes dia año 





La identificación del paciente es esencial para poder asegurar la correcta recopilación de 
datos, sin embargo, el paciente no está obligado a dar su nombre si es que no lo desea, 
sin embargo, los demás datos son OBLIGATORIOS,
 
 debe recordarse al paciente que 
estos datos de ninguna manera implica que su atención médica o demás derechos serán 
afectados, al contrario, que de existir un diagnóstico de Leptospirosis o Dengue, se lo 
hará conocer de una manera rápida y oportuna, y que esta es la real implicación de llenar 
este apartado de la encuesta. Si el paciente no desea que se incluya su nombre en la 
encuesta, debe recordarse que todas las encuestas llevan un código que servirá para la 
identificación de la muestra que acompaña a la encuesta. 
II. PRESENTACION CLINICA 
 
La presentación clínica de la enfermedad es uno de los apartados más importantes  de la 
encuesta,  en lo posible debe llenarse todos los espacios, se debe recordar que 
1.1 Nombre del paciente 
1.2 Edad: 
1.3 Fecha  nacimento: mes dia año 
1.4 Sexo: 




1.5 Dirección del domicilio: 
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lospacientes no manejan muchas veces los términos médicos,  por tal razón debe 
explicárselos de manera concisa y en lenguaje común, sin embargo es el personal de 
salud que está recogiendo la encuesta  quien llene los espacios en este apartado, pues 
involucra criterio médico y diagnóstico presuntivo. La temperatura y frecuencia 
respiratoria son tomados en el momento de la encuesta. 
2.1 Cuántos días ha estado enfermo (a)? 
2.2 Fiebre: 
Si   No    
 
Temperatura 
2.3 Tomó antibiótico? 
Si   No   No sabe  
 
2.4 Ictericia: 
Si   No   
 
2.5 Sufusión  Conjuntival: 
Si   No   
 
2.6 Dificultad respiratoria: 
Si   No   
 
2.7 Hemoptisis: 
Si   No   
 
2.8 Frecuencia Respiratoria : 
2.9 Oliguria 
Si   No   No sabe  
 
2.10 Dolor muscular/articular 
Si   No   
 
 
Localización del dolor 
2.11 Dolor de cabeza 
Si   No   
 








III. Factores de riesgo: 
 
El siguiente apartado, nos ayudará a investigar cuales son las condiciones de vida más 
prevalentes que involucran el riesgo de la enfermedad, son realmente importantes que se 
llene por completo este apartado, sin  embargo, las respuestas pueden ser variables, o 
pueden existir casilleros que queduen vacíos, por ejemplo, el apartado 3.12 averigua 
sobre la presencia de ratas, si la respuesta es negativa, los apartados, 3.13  y 3.14 se 
anulan automáticamente. 
Las preguntas que tengan como respuesta si o no, no deben contener aclaraciones 
extras,  cuando existe la posibilidad de añadir algún dato,  realizarlo de forma clara y 
consisa. No poner más datos de los requeridos. 
En el apartado 3.2, acerca del trabajo del paciente encuestado, puede existir la 
posibilidad de anotar otra ocupación, sin embargo debe relacionarse con la patología a 
investigar, y que preferentemente tenga factores de riesgo de desarrollo de leptospirosis 
y/o dengue, (que pueda tener contacto con agua contaminada) Ej. Recolector de Basura, 
Bombero. 
Los demás acápites se  llenarán de acuerdo a su contenido.  
3.1 Su casa esta construída sobre agua?: 






















a. Alcantarilla desagües  Si   No   
        
b. Constrcuccion  Si   No   
        
c. Vendedor ambulante  Si   No   
        
d. Agricultura/ganaderia  Si   No   
        
e. Mecanico  Si   No   
        
f. estudia  Si   No   
 
3.3 
Trabaja en el  barrio que vive?                                              
Si   No   
 
3.4 
DURANTE LAS ULTIMAS TRES SEMANAS
 
 USTED ESTUVO :  
EN CONTACTO CON LODO 
       
a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o 
botas? 
Si   No   
3.5 








a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o 
botas? 





EN CONTACTO CON AGUA DE INUNDACION 
  
 a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o 
botas? 
Si   No   
 
3.7 
EN CONTACTO CON AGUA DE ALCANTARILLA 
 
 
       
a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o 
botas? 
Si   No   
DURANTE LAS ULTIMAS TRES SEMANAS 
3.8 







a. cerca de casa? Si   No   
       
b. en el  trabajo? Si   No   
En caso afirmativo       
Usó guantes o 
botas? 
Si   No   
3.9 
Se inundó su casa durante la lluvia? 
Si   No   
 
3.10 
Se inundó la calle cercana a su casa por la lluvia? 
Si   No   
 
3.11 
Se inundó su lugar de trabajo 






Ha visto ratas ultimamente? 
  a. Cerca de la casa  Si   No  
       
b. Cerca del trabajo  Si   No  
3.13 
 
Cuantas ratas ha visto juntas? 
 
a. Cerca de la casa?   
   
b. En el trabajo?   
3.14 
 
Ha visto ratas caminando durante el día? 
   
                   a. Cerca de la casa  Si   No  
       
b. En el trabajo  Si   No  
3.15 
Tienen perro en la casa o los perros de su vecino visitan su casa? 
No    Si   
 
3.16 
Tienen gato en casa? 
No    Si   
 
3.17 
Tiene gallinas en casa? 
No    Si   
 
3.18 







7.5 Appendix 4 
DECLARACIÓN DE CONSENTIMIENTO INFORMADO 
 
 
Yo,  _____________________, de ____años de edad, con CI Nº _______________, manifiesto que 
me han explicado y entiendo la importancia que tiene mi contribución a este estudio, para 
investigar la  presencia de Leptospirosis (enfermedad grave transmitida por ratas y perros) y 
Dengue (enfermedad transmitida por mosquitos). 
 
He sido informado/a de que mis datos personales no serán entregados a nadie.  
También se me ha indicado que mi colaboración es voluntaria y que puedo decidir no 
participar.  
  
ACEPTO donar tres gotas de mi sangre para este estudio y llenar la encuesta solicitada.  
 
Firma Paciente    Firma Investigador  
  CI:      CI: 
 
Fecha: 
Cualquier pregunta favor dirigirse a:  
Dr. Andrés Abril G,  e-mail: aabril@usfq.edu.ec,   
Dirección: Diego de Robles y Pampite, Círculo de Cumbayá(Universidad San Francisco de Quito) 






7.6 Appendix 5 
Indicaciones y responsabilidades para el Investigador al momento de 
obtener el consentimiento informado 
 
• La Obtención del consentimiento informado para la participación de sujetos humanos en 
investigación biomédica es el aspecto más importante y crítico a la vez, en el reclutamiento de 
voluntarios, y se debe tener presente que constituye un proceso interactivo y dinámico que no 
termina con la firma del consentimiento informado si no que se prolonga durante todo el estudio. 
 
• Al elaborar el consentimiento informado, el investigador debe usar un lenguaje claro y 
sencillo, de preferencia con expresiones usadas comúnmente en nuestro país para mencionar 
enfermedades o situaciones especiales, que aclaren o faciliten el entendimiento del estudio. 
 
• Obtener el consentimiento informado del candidato voluntario que participará en la 
investigación o, en caso de que la persona carezca de capacidad de dar su consentimiento 
informado, el consentimiento podrá obtenerse por poder de un representante debidamente 
autorizado. 
 
• Proporcionar al candidato voluntario, toda la información relevante respecto al estudio 
que se va a realizar para que pueda dar su consentimiento sin dudas ni temores. 
 
• Ofrecer al candidato voluntario, amplias oportunidades de hacer preguntas con respecto 
a sus dudas y temores, estar dispuesto y seguro a contestarlas, de manera clara y amable. 
 
• Asegurarse que el posible voluntario comprenda esta información. Los investigadores 
pueden solicitar a los participantes que discutan la información que han recibido, se pueden hacer 
las siguientes preguntas: ¿Me puede decir cuál es el propósito de nuestro estudio? ¿Cuáles son 
los riesgos del estudio?  
 
• Darle el tiempo suficiente para discutir su participación si él lo desea, con familiares o 




• Excluir toda posibilidad de persuasión encubierta injustificada, influencia indebida o 
intimidación, no ofrecer estímulos que posteriormente no se los podrá cumplir. 
 
• El presunto voluntario o su representante autorizado debe firmar el documento que 
acredite su consentimiento y debe entregársele una copia del mismo. 
 
• Renovar el consentimiento informado de cada participante si las condiciones o 
procedimientos de la investigación sufren modificaciones importantes. 
 
• Se debe tener especial atención para cubrir las necesidades de poblaciones vulnerables 
como los niños, los enfermos en estado crítico, mentalmente incapacitados o las comunidades 







7.7 Appendix 6 
Impacto de la  Leptospirosis en Barrios Marginales de  Guayaquil 
 
Fecha  mes dia año 






II. PRESENTACION CLINICA 
 
2.1 Cuántos dias ha estado enfermo (a)? 
2.2 Fiebre: 
Si   No    
 
Temperatura 
2.3 Tomó antibiótico? 
Si   No   No Hay datos  
 
2.4 Ictericia: 
Si   No   No Hay datos  
 
2.5 Sufusión Conjuntival: 
Si   No   No Hay datos  
1.1 Nombre del paciente 
1.2 Edad: 
1.3 Fecha de nacimento: mes dia año 
1.4 Sexo: 
Masculino   Femenino   
 




2.6 Dificultad respiratoria: 
Si   No   No Hay datos  
  
2.7 Hemoptisis: 
Si   No   No Hay datos  
  
2.8 Frecuencia Respiratoria: 
 
2.9 Oliguria 
Si   No   No Hay datos  
  
2.10 Dolor muscular/articular 
Si   No       
 
 
Localización del dolor 
2.11 Dolor de cabeza 
Si   No   No Hay datos  
  
2.12 Diagnóstico inicial: 
Dengue   Leptospirosis               Malaria  
 
 
III. DIAGNÓSTICO Y TRATAMIENTO  
 
3.1 Métodos Diagnósticos 
3.2 Presuntivo: 
Si   No    
 
Critérios 
3.3 Confirmatorio por laboratorio? 





Si   No   
  
3.5 MEDIDAS FARMACOLÓGICAS? 
3.6 Hospitalización? 
Si   No     
  
3.7 Farmacoterapia? 




3.8 Terapia Múltiple 
Si   No   
  
3.9 Diagnóstico confirmado 
Dengue   Leptospirosis               Malaria  
  
 
IV. EVOLUCIÓN CLINICA 
 
4.1 Cuántos dias de seguimiento 
4.2 Fracaso terapéutico 




Si   No   No Hay datos  
 
4.4 Nueva Hospitalización  
82 
 
Si   No   
  
4.5 Transferencia: 
Si   No   
  
4.6 Muerte: 
Si   No   
  
 
V. Factores de riesgo: “Solo si existen” 
 
5.1 Casa esta construída sobre agua?: 



















a. Alcantarilla desagües  Si   No   
        
b. Constrcuccion  Si   No   
        
c. Vendedor ambulante  Si   No   
        
d. Agricultura/ganaderia  Si   No   
        
e. Mecanico  Si   No   
        




EN CONTACTO CON LODO 
 
Si   No   No Hay datos  
       
5.5 
EN CONTACTO CON BASURA 
  




EN CONTACTO CON AGUA DE INUNDACION 
  




EN CONTACTO CON AGUA DE ALCANTARILLA 
 
Si   No   No Hay datos  
      
5.8 
Tienen perro en la casa? 
Si   No   No Hay datos  
 
5.9 
Tienen gato en casa? 
Si   No   No Hay datos  
 
5.10 
Tiene gallinas en casa? 
Si   No   No Hay datos  
 
5.11 
Tiene otro animal en la casa? 

















7.8 Appendix 7 
MANUAL DE PROCEDIMIENTOS 
I. CAPACITACIÓN DE TOMA DE MUESTRAS SEROLÓGICAS 
El personal destinado para la toma de muestras serológicas será escogido mediante un 
proceso previo de selección. El proceso de capacitación será realizado mediante 
presentaciones y demostraciones prácticas de las guías de procedimientos.  El 
entrenamiento para la recolección, cuidado y almacenamiento de los especimenes de 
colectados en conjunto con las encuestas escritas será dirigido a supervisores de área y 
entrevistadores.  Mientras que el entrenamiento para el proceso utilizado en la 
recolección, cuidado y almacenamiento de muestras de laboratorios será dirigido a 
técnicos de laboratorio y a los supervisores de área.  
Posterior al entrenamiento, se realizarán entrevistas prácticas en grupos pequeños con el 
objetivo de escoger al personal idóneo.  La correspondiente guía de procedimientos será 
entregada a cada uno de los supervisores y entrevistadores elegidos.  
RESPONSABILIDAD DE CADA UNA DE LAS PERSONAS INVOLUCRADAS 
DURANTE EL PROCESO DE RECOLECCION DE LAS MUESTRAS 
 
Recolectores de muestras de laboratorio: 
Deberán recorrer cada uno de los laboratorios asignados recolectando y preparando las 
muestras de sangre.  Para el proceso de recolección deberán seguir el protocolo descrito 
en la guía de procedimientos detallada a continuación.  Durante el proceso de recolección  
asignarán un código a cada muestra. Finalmente deberán entregar las muestras al 
supervisor de área.  
Encuestadores: 
Su función será la de recolectar las muestras de gota seca de sangre utilizando el 
procedimiento detallado a continuación,  el tiempo necesario para recolectar cada 
muestra se estima en 5 minutos. En este tiempo, deben cambiar de guantes a un par 
nuevo, tomar la muestra, rotularla con el código asignado y colocarla cuidadosamente en 
la caja destinada para este fin (detallado a continuación en la guía de procedimientos). 
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Supervisores de área:  
Dependiendo de la cantidad de muestras, pueden existir supervisores de área, caso 
contrario, solo existirán encuestadores. Los supervisores estarán  capacitados para 
realizar un control de calidad (detallado a continuación en la sección de control de 
calidad) y almacenamiento (detallado a continuación en la guía de procedimientos) tanto 
de las muestras de laboratorio como las muestras recolectadas durante las entrevistas.  
Las muestras de gota de sangre seca serán mantenidas en un lugar seco y enviadas en 
un sobre al laboratorio en Quito.  El supervisor deberá llevar un control de las muestras 
recibidas  con la identificación respectiva de los encuestadores y recolectores de 
muestras de laboratorio.  
GUIAS DE PROCEDIMIENTOS 
Incluyen todo el proceso desde la toma de muestra, cuidados y precauciones, hasta su 
almacenamiento y envió al laboratorio de la USFQ en donde serán procesadas. Se 
llenará un formulario durante la toma de  muestras, esto permitirá llevar un orden además 
de ser parte del control de calidad de las muestras.   
MUESTRAS DE SANGRE DE  LABORATORIOS 
Recolección y preparación de muestra 
Las muestras de sangre deben estar en tubos con anticoagulante (como la heparina, 
citrato o EDTA). Generalmente estos tubos tienen tapa morada o tapa verde. La muestra 
de sangre no debe ser centrifugada.  
1. Ponerse guantes antes de manipular los tubos  
2. Antes de iniciar colocar el código de la muestra en el extremo derecho del papel 
filtro.  
3. Agitar el tubo en donde se encuentra la sangre de tal manera que la sangre se 
mezcle bien. 
4. Con la pipeta plástica nueva,  se debe tomar  una pequeña cantidad de sangre y  
se deja caer la sangre (gota por gota) sobre el círculo marcado en el papel filtro.  
De tres a cinco gotas serán depositadas hasta llenar el círculo que se encuentra 
dibujado en el papel filtro.   
5. PARA CADA MUESTRA DE SANGRE SE DEBE USAR UNA PIPETA PLASTICA DIFERENTE.  
LUEGO QUE SE HA USADO UNA PIPETA PLASTICA, ESTA DEBE SER COLOCADA EN EL 
RECIPIENTE DE BASURA CONTAMINADA.   
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6. Tener mucho cuidado en que no salpique sangre de un tubo en el papel filtro 
porque se pueden mezclar sangres diferentes.  Si esto llegara a ocurrir, desechar 
el papel filtro y repetir el proceso utilizando un papel filtro nuevo. 
7. Los papeles filtro con la gota de sangre deben ser luego secados a temperatura 
ambiente por 4 horas ( 24 horas en la costa ) en posición horizontal. Utilizando un 
alfiler, sujetar cada muestra sobre la lámina de corcho que se encuentra en la 
caja.   
 
Como se guardan las muestras 
1. Una vez secas las muestras se  coloca cada muestra en una funda de papel encerado, 
de tal manera que cada fundita contenga un solo papel filtro. Grapar el extremo superior 
de la fundita de tal manera que el papel filtro no salga de ella en ningún caso. Las 
muestras deben estar completamente secas antes de ser guardadas, de lo contrario hay 
el riesgo de que se contaminen. 
 CUIDADO: Colocar el papel filtro con la muestra en el lugar designado para este 
propósito y no permitir que éstos toquen otras superficies ni durante ni después de que se 
sequen. 
                                               
2. Finalmente, las muestras serán colocadas en una funda plástica junto con una fundita 
de silica.  Cada funda plástica “zip lock”  contendrá entre 15 a 20 muestras y será 
colocada dentro de un sobre de Manila.  El sobre será entregado a cada uno de sus 
supervisores de área quienes son los encargados de revisar y enviar las muestras a al 
laboratorio de Quito. 
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.                
3. La siguiente información debe ser enviada junto a las muestras.  
Nombre del laboratorio:_________________ 
Provincia:____________________________ 
Ciudad:______________________________ 
Nombre del supervisor :_________________               tlf: ___________ 
Nombre de la persona que colecta la muestra _____________  tlf__________ 







Precauciones a tener durante la recolección y el manejo de la muestra 
1. La toma de muestras solo debe llevarse a cabo por personal entrenado. 
2. Usar un par de guantes durante todo el procedimiento.  El uso de guantes 
disminuye la incidencia de contaminación con sangre.  
3.  No lavar los guantes con agentes desinfectantes, esto puede causar la 
penetración de líquidos por agujeros imperceptibles. 
4. No manipular las muestras sin guantes. 
5. Todos los materiales contaminados con sangre deben ser eliminados previa 





Desechar el material corto punzante en el sitio destinado con este propósito, no ponga en 
el tarro de basura.  
.MUESTRAS RECOLECTADAS DURANTE LAS ENCUESTAS ESCRITAS: GOTA DE 
SANGRE SECA 
Para tomar la muestra de sangre se deben seguir los pasos que se describen a 
continuación. 
Preparación del Accu Check Softclix 
El Accu Check Softclix es un punzador, que  sirve para pinchar el dedo y obtener la 
muestra de sangre de cada una de las muestras. Cada vez que se desee obtener una 
muestra, se debe cambiar de aguja, por ningún motivo se utilizará la misma aguja para 
obtener una muestra de sangre de dos personas diferentes.  
1. Ajustar la profundidad del pinchazo: Con la parte delantera de la tapa del Accu-
Chek Softclix puede ajustar la profundidad del pinchazo a su propio espesor de 
piel.  
                                                  
2. Sacar la tapa:  A continuación, saque la tapa del Accu-Chek Softclix para poder 
colocar la lanceta Accu-Chek Softclix II. 
   
                                             
3. Colocar la lanceta: Coloque la lanceta hasta escuchar un claro clic. Quite luego la 
cobertura de protección de la lanceta y vuelva a colocar la tapa del Accu-Chek 
Softclix. Fíjese en la pequeña ranura ubicada en eborde blanco de la tapa y 
asegúrese que esté orientada hacia el centro del agujero en forma U en el 
punzador. 
 




4.  Tensar el Accu-Chek Softclix: Presione el botón en el lado posterior del Accu-
Chek Softclix para tensar el punzador. Puede controlar que esté tensado 
comprobando si el botón destensador tiene un color amarillo.   
 
                                                   
5. Sacar sangre: Antes de pinchar es importante lavarse las manos con agua 
caliente y luego secarlas bien. Para pinchar, elegir de preferencia el costado de la 
yema del dedo índice o anular. Coloque el Accu-Chek Softclix contra su dedo y 
presione el botón destensador amarillo. 
 
                                                   
 
6. Expulsar la lanceta: Para evitar infecciones y para seguir pinchando con el menor 
dolor posible, le recomendamos usar la lanceta sólo una vez. Después de 
utilizarla puede expulsar la lanceta en un contenedor de basura. Para eso, 
presione la parte posterior del Accu-Chek Softclix y al mover el mecanismo de 
expulsión hacia adelante, la lanceta usada caerá.  
   




Recolección de muestra 
                          
Antes de recolectar la muestra, el papel filtro debe ser rotulado con el mismo código que 
se encuentra en la esquina superior de la encuesta que el paciente está llenando.  
Las muestras deben ser tomadas del pulpejo digital anular. Para obtenerla se debe 
masajear hacia  arriba de tal manera que la sangre se acumule en la yema del dedo. 
 
A continuación se limpia  el pulpejo del dedo con alcohol isopropílico o metanol al 70% y  
se procede a punzar con la lanceta estéril.  La primera gota debe ser eliminada 
limpiándola con una torunda.  Si el pinchazo inicial es inadecuado, no pinchar 
nuevamente en el mismo sitio, otro dedo debe ser utilizado y se debe cambiar a una 
nueva aguja.  
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Nota: descartar la aguja utilizada en el recipiente marcado para “desechos 
cortopunzantes”. Por ningún motivo se debe reutilizar esta aguja para realizar un nuevo 
pinchazo. 
 
Las siguientes tres a cinco gotas serán depositadas hasta llenar el circulo que se 
encuentra dibujado en el papel filtro. Una buena muestra debe dar como resultado una 
circunferencia  saturada de sangre, de 1.5 cm de diámetro.  CUIDADO:  No intentar 
esparcir la gota ni topar el papel filtro con el dedo. No utilizar los dos lados del papel filtro 
para colectar la muestra. 
Almacenamiento y envío de muestra 
            
Los papeles filtro con la gota de sangre deben ser luego secadas a temperatura ambiente 
por 4 horas (24 horas en zonas húmedas) en posición horizontal. Utilizando un alfiler, 
sujetar cada muestra sobre la tira de corcho ubicada en la caja de trabajo que se les 
proveerá. CUIDADO: Colocar el papel filtro con la muestra en el lugar designado para 
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este propósito y no permitir que éstos toquen otras superficies ni durante ni después de 
que se sequen. 
                             
 
Una vez transcurrido el tiempo de secado, cada tira de papel filtro con la gota de sangre 
completamente seca, será introducida en una funda de papel encerado.  La funda 
plástica debe ser grapada en la parte superior para que no se salga la muestra, de tal 
manera que no queden herméticamente cerradas.  Solo se podrá colocar una muestra en 
cada fundita. Todo esto con el objetivo de que la muestra no se contamine ni tenga 
contacto con las demás muestras.  Las muestras deben estar completamente secas 
antes de ser guardadas, de lo contrario hay el riesgo de que se contaminen. 
 
              
 
Luego, las muestras serán colocadas en una funda plástica junto con una fundita de silica 
(la cual deberá ser perforada con un alfiler antes de ser introducida en la funda plástica).  
Cada funda plástica “zip lock”  contendrá entre 15 a 20 muestras (cada una previamente 
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colocada en una funda pequeña) y será colocada dentro de un sobre de Manila.  El sobre 
será entregado a cada uno de sus supervisores de área quienes son los encargados de 
revisar y enviar las muestras a al laboratorio de la USFQ en Cumbayá - Quito. 
Precauciones y cuidados a tener durante la recolección de la muestra 
1. La toma de muestras solo debe llevarse a cabo por personal entrenado. 
2. Usar un par de guantes por cada paciente. El uso de guantes disminuye la incidencia 
de contaminación con sangre.  
3.  No lavar los guantes con agentes desinfectantes, esto puede causar la penetración 
de líquidos por agujeros imperceptibles. 
4. No manipular las muestras secas sin guantes. 
5. Desechar el material corto punzante en el sitio destinado con este propósito, no en el 
tarro de basura cotidiana.  
6. Todos los materiales contaminados con sangre deben ser eliminados previa 
neutralización  por medios térmicos o con una solución de hipoclorito de sodio al 
0.5%, por esta razón los desechos deben ser llevados al laboratorio indicado para que 
allí sean decontaminados. 
 
II. ANÁLISIS DE LABORATORIO 
Para el análisis de laboratorio se utilizará el kit comercial  IGM Elisa  Leptospirosis y/o 
Dengue (PanBio, Australia). Según las especificaciones del fabricante. 
III. CONTROL DE  CALIDAD 
Control de calidad del trabajo de campo 
1. Los datos del entrevistador ( Nombre, teléfono, ciudad, provincia y área) serán 
enviados con cada sobre para poder identificar el origen de las muestras. 
2.  En el caso de las muestras de suero o plasma provenientes de laboratorios, se deberá 
llenar un formulario que provea de el nombre del laboratorio, los códigos de las muestras 
y  el nombre del responsable. 
3. Cada encuestador, revisará la calidad y cantidad de las muestras, así como la 
rotulación de cada una.   
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4.  El responsable deberá tener un registro con los códigos de todas las muestras a su 
cargo. 
5. Una vez chequeadas las muestras, el responsable,  las empacará y las enviará al 
laboratorio para su procesamiento. 
IV. ANALISIS Y ENTREGA DE DATOS 
Los datos serán analizados y entregados en una tabla en donde se especifique el código 
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